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ABSTRACT 
GENETICS AND MECHANISMS OF ESSENTIAL 
TREMOR AND RELATED DISORDERS 
 
Hilal Ünal Gülsüner 
Ph.D. in Materials Science and Nanotechnology 
Advisor: Assist. Prof. Dr. Ayşe Begüm Tekinay 
January, 2015 
Neurodegenerative disorders are characterized by progressive nervous system 
dysfunction, and they remain as one of the most challenging disorders known to 
humankind. These disorders have devastating effects on patients and currently there are 
no effective therapeutic approaches. Approved medicines provide only symptomatic 
relief, and inadequacy of information about the molecular mechanisms underlying these 
conditions restricts the development of new effective therapies. In this thesis, I 
presented the genetic analysis of two different neurodegenerative disorders and 
investigate the molecular mechanisms underlying these two disorders: essential tremor 
and Troyer syndrome. Essential tremor is one of the most prevalent movement 
disorders; however, its genetic cause and molecular mechanisms remain unknown 
because of its clinical heterogeneity, age-dependent penetrance, variable expressivity, 
and relation to other neurodegenerative disorders. In a six-generation consanguineous 
Turkish family with both essential tremor and Parkinson’s disease, we identified a rare 
missense mutation of HTRA2 as the causative allele. Family members homozygous for 
this allele were more severely affected than those heterozygous for this allele. Troyer 
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syndrome is a very rare autosomal recessive neurodegenerative disorder with only 
several described cases. Only two reports with truncating mutations have been 
described. In a consanguineous Turkish kindred with two affected siblings presenting 
tremor of the hands as well as clinical features similar to that of Troyer syndrome, we 
identified a novel missense mutation in SPG20. We presented a genotype-phenotype 
correlation in this family, and the missense SPG20 p.G580R mutation was found to 
result in a milder form of Troyer syndrome without skeletal abnormalities. Overall, this 
study provides solutions to complexities of neurodegenerative disorders by suggesting a 
novel and unifying molecular mechanism underlying essential tremor and Parkinson’s 
disease. Furthermore, correlation of genotypes and phenotypic differences in patients 
with Troyer syndrome explains the clinical heterogeneity and variable expressivity of 
neurodegenerative disorders. 
 
 
 
 
 
 
Keywords: Disease gene identification, Essential tremor, hereditary movement 
disorders, mutation, next-generation sequencing, Troyer syndrome.  
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ÖZET 
ESANSİYEL TREMOR VE BENZERİ 
HASTALIKLARIN GENETİĞİ VE MEKANİZMASI 
 
Hilal Ünal Gülsüner 
Malzeme Bilimi ve Nanoteknoloji Programı, Doktora 
Tez Danışmanı: Yard. Doç. Dr. Ayşe Begüm Tekinay 
Ocak, 2015 
Nörodejeneratif hastalıklar ilerleyici sinir sistemi bozuklukları olarak tanımlanırlar ve 
insanlık tarihinde karşılaşılan en zorlu hastalıklardır. Hastalar üzerindeki etkileri çok 
tahrip edici boyutlara ulaşabilen nörodejeneratif hastalıkların etkili bir tedavi yöntemleri 
bulunmamaktadır. Günümüzde kullanılan tedavi yaklaşımları sadece bu hastalıkların 
belirtilerini azaltmaya yöneliktir. Günümüzde bu tür hastalıkların altında yatan 
moleküler mekanizmalar ile ilgili yeterli bilgiye sahip olunmaması, yeni ve etkili tedavi 
yöntemlerinin geliştirilebilmesi konusunda çok büyük engel teşkil etmektedir. Bu 
çalışmada iki farklı nörodejeneratif hastalık olan esansiyel tremor ve Troyer 
sendromunun genetik incelemeleri sunulmuştur. Esansiyel tremor en sık görülen hareket 
bozukluklarından biri olmasına rağmen, bu hastalığın klinik heterojenliği, yaşa bağlı 
penetransı, değişken ifade edilmesi ve diğer nörodejeneratif hastalıklar ile olan 
benzerlikleri nedeniyle genetik ve moleküler kökenleri henüz tam olarak tespit 
edilememiştir. Bu çalışmada, Türkiye’de yaşayan, esansiyel tremor ve Parkinson 
hastalarının görüldüğü ve akraba evliliği olan 6 kuşaklık bir aile tanımlanmıştır. Bu 
ailedeki 3 hastadan alınan DNA ile gerçekleştirilen tüm ekzom dizilemesi sonucunda 
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HTRA2 geninde hastalık yapıcı bir yanlış anlamlı mutasyon tespit edilmiştir. Bu 
mutasyonu homozigot olarak taşıyan kişilerde hastalık belirtileri heterozigot bireylere 
göre çok daha şiddetlidir ve bu bireylerde orta yaştan itibaren Parkinson hastalığı 
gelişmiştir. Troyer sendromu ise çok nadir görülen otozomal çekinik bir hastalıktır. Bu 
hastalığın nedeni olarak şu anda kadar sadece SPG20 geninde protein ifadesini yok eden 
iki farklı çerçeve kayması mutasyonu tanımlanmıştır. Bu çalışmada, el titremesi ile 
birlikte Troyer sendromu belirtilerini taşıyan ve akraba evliliği sonucu dünyaya gelmiş 
iki kardeş tanımlanmıştır. Bu iki hasta bireyden izole edilen DNA ile gerçekleştirilen 
tüm ekzom dizileme çalışmaları sonucunda SPG20 geninde yeni bir yanlış anlamlı 
mutasyon keşfedilmiştir. Bu ailede saptanan SPG20 p.G399S mutasyonu, tanımlanan 
diğer Troyer vakalarından farklı olarak, iskelet anomalilerine neden olmamaktadır. Bu 
çalışmalar esansiyel tremor ve Parkinson hastalıklarında yeni ve birleştirici bir 
mekanizma sunarak, nörodejeneratif hastalıkların karmaşık yapılarına bir çözüm 
getirmektedir. Ayrıca, Troyer sendromlu ailede tanımladığımız fenotip şiddeti ile 
genotip arasında saptanan ilişki, nörodejeneratif hastalıkların klinik heterojenliği ve 
değişken ifadelerini aydınlatmaktadır. 
 
 
 
 
 
 
Anahtar sözcükler: Esansiyel tremor, hastalık gen tanımlanması, kalıtsal hareket 
bozuklukları, Troyer sendromu, yeni nesil dizileme. 
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Chapter 1 
1 Introduction 
1.1 Neurodegenerative Disorders  
Neurodegeneration is the loss of the structure and death of the neurons in motor, 
sensory or cognitive systems. Neurodegenerative disorders are characterized by 
progressive nervous system dysfunction which begins insidiously and follow a slow but 
progressive course. The level of neurodegeneration can range from molecular to cellular 
levels. Individuals first have mild symptoms like problems in coordination or memory. 
However, as cells start to deteriorate, symptoms progressively get worse, such as 
patients might lose their ability to walk, move, or think clearly.  
There are more than a few hundreds of neurodegenerative disorders. Most of 
them overlap with each other clinically and pathologically. Neurodegenerative disorders 
can be classified depending on the pattern of cell loss in different regions of the brain. 
They are grouped into the basal ganglia, brainstem and cerebellum, cerebral cortex, or 
spinal cord disorders (1) (Table 1). Basal ganglia disorders are characterized by 
abnormal movements or defects in the initiation of motor function (2). Parkinson’s 
disease, which is characterized by loss of dopaminergic neurons and presence of Lewy 
bodies, is a hypokinetic basal ganglia disorder; that is, higher than normal basal ganglia 
output causes inhibition of thalamocortical neurons and reduces motor function (2). 
Huntington’s disease is characterized by chorea and is a hyperkinetic basal ganglia 
disorder. It is caused by reduced basal ganglia output, which increases thalamocortical 
  
2 
 
function and uncontrollable motor function (2). Essential tremor, Friedreich’s ataxia, 
multiple systems atrophy, and spinocerebellar ataxia are examples of brainstem and 
cerebellum disorders. Classification of diseases that predominantly affect brainstem and 
cerebellum is especially challenging because of the overlap among pathological 
symptoms. Cerebral cortex is cerebrum’s outer layer and plays a key role in memory, 
language, attention, perceptual awareness, and consciousness (3). One of the disorders 
that occur due to damage in cerebral cortex is Alzheimer’s disease which is 
characterized with neuropathological features of neuronal loss, senile plaques, 
neurofibrillary tangles and acetylcholine deficiency. Diffuse Lewy body disease and 
Pick’s disease are other examples of cerebral cortex disorders. Spinal cord supports 
nerve cells that extend from medulla oblongata to brainstem. Defects in spinal cord 
destroy motor neurons which function in voluntary muscle activities such as speaking, 
walking, breathing and swallowing (3). The neurodegenerative diseases with defective 
spinal cord are hereditary spastic paraplegia, amyotrophic lateral sclerosis, and spinal 
muscular atrophy.  
Central nervous system diseases remain one of the most challenging disorders 
known to humankind. Neurological disorders have devastating affects to patients and 
there is no effective therapeutic approach. Currently, medications can only provide 
symptomatic relief, and the development of new effective therapies is prevented by the 
limited knowledge of the molecular mechanisms underlying these conditions.  
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Table 1.1 Clinical and pathological features of hereditary neurodegenerative disorders 
and the list of mutated genes 
Disease and Predominantly  
Affected Site 
Neuropathological 
Features 
Mutated Genes
* 
Basal Ganglia 
 
Huntington’s disease 
neuronal loss in 
neurostriatum and 
cerebral cortex 
HTT 
Parkinson’s disease 
neuronal loss in 
substantia nigra, Lewy 
bodies in pigmented 
neurons 
EIF4G1, LRRK2, PARKIN, PARK7, 
PINK1, SNCA, VPS35 
Brain stem and Cerebellum 
 
Essential tremor 
large Bergmann glial 
cells and torpedoes in 
cerebellum 
FUS, DNAJC13 
Friedreich’s ataxia 
neuronal loss in motor 
and sensory systems 
FXN 
Multiple system atrophy 
neuronal and glial 
inclusions 
SNCA 
Spinocerebellar ataxia 
neuronal loss in 
cerebellum and 
brainstem 
Multiple genes (e.g. ATXN1, 
ATXN2, ATXN3, C10ORF2)  
Cerebral Cortex 
 
Alzheimer’s disease 
senile plaques, 
neurofibrillary tangles, 
neuronal and synaptic 
loss 
APP, PSEN1, PSEN2 
Pick’s disease 
frontotemporal atrophy, 
pick bodies 
NPC1, NPC2, SMPD1 
Spinal cord 
 
Amyotrophic lateral sclerosis 
loss of upper and lower 
motor neurons, Bonina 
bodies and axonal 
spheroids 
ANG, ALS2, C9ORF72, FIG4, FUS, 
OPTN, SETX, SOD1, SPG11, 
TARDBP, UBQLN2, VAPB, VCP 
Hereditary spastic paraplegia 
loss of lower motor 
neurons 
Multiple genes (e.g. ATL1, 
KIAA0196, PLP1, SPG7, SPG11, 
SPG20, SPAST, ZFYVE26) 
Spinal muscular atrophy 
loss of lower motor 
neurons 
DYNC1H1, SMN1, SMN2, UBA1, 
VAPB 
*
Only established Mendelian disease genes are listed, susceptibility loci are not included.  
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1.2 Genetics and Mechanisms of Neurodegenerative 
Disorders  
In addition to their extensive clinical diversity, most of the neurodegenerative 
disorders are genetically heterogeneous. However, the insights gained through genetic 
studies reveal some overlapping mechanisms (4). These include protein aggregation, 
oxidative stress, excessive reactive oxygen species formation, mitochondrial 
dysfunction, energy depletion and autophagy disruption, endoplasmic reticulum stress, 
neuroinflammation, and several environmental factors.  
1.2.1 Protein misfolding and aggregation 
Proteins form networks based on their physical interactions and these networks 
determine every aspect of life to ensure that cells and organisms function properly. 
Proteins must maintain their three dimensional structures to stay functionally active in 
such networks. Chaperone proteins organize protein folding in order to prevent mistakes 
and malfunctioning proteins. However, partial protein folding or misfolding, 
aggregation and deposition have been observed in the brain tissues of neurodegenerative 
disorders. These disorders are classified as protein conformational diseases or 
proteinopathies (5). Some examples of proteinopathies are CAG trinucleotide repeat 
expansion diseases such as Huntington’s disease and spinocerebellar ataxias (6). 
Parkinson’s disease, amyotrophic lateral sclerosis, prion disease, and Alzheimer’s 
disease are also classified as proteinopathies (6). The most important feature of these 
proteinopathies is that a certain protein folds into an alternative stable conformation 
which results in its aggregation in the tissues (6). Examples of the aggregated proteins 
are α-synuclein (encoded by SNCA) in Parkinson’s disease, amyloid-β (cleaved from 
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amyloid-β precursor protein (APP) with the help of enzymes encoded by presenilin1 
(PSEN1) and presenilin 2 (PSEN2)) in Alzhemier disease, huntingtin (encoded by HTT) 
in Huntington’s disease and superoxide dismutase (encoded by SOD1) in amyotrophic 
lateral sclerosis (6).  
The link between protein aggregation and neurodegeneration is not well 
understood. The hydrophobic patches of these aggregated proteins might interact with 
other components of the cell and cause damage. In addition, these proteins are part of 
essential cellular networks, including chromatin organization, vesicular transportation, 
transcription and translation, cell architecture and protein quality control (7). Therefore, 
their misfolding and aggregation results in disintegration of these crucial cellular 
functions (7).  
There are several systems used by eukaryotes to remove the malfunctioning 
proteins and to prevent their aggregation. Cells have protein quality control pathways in 
order to avoid defects in protein homeostasis. The protein homeostasis is regulated by 
molecular chaperones, autophagy and ubiquitin proteosome system (UPS) (PARKIN, 
which is mutated in AD, involves in UPS) to clear proteins expressed in abundance. 
However, these protein control mechanisms become overwhelmed with age by several 
genetic and environmental factors. Therefore misfolded proteins can contribute to 
neurodegenerative disorders by loss-of-function of the protein aggregates, gain-of-toxic-
activity, or by causing brain inflammations (6).  
1.2.2 Mitochondrial dysfunction and oxidative stress 
Mitochondria are present in all cells of the body except erythrocytes and range 
from hundreds to thousands in number. They provide an organism’s housekeeping 
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functions, including production of the adenosine triphosphate (ATP), biosynthesis of 
aminoacids, beta-oxidation of fatty acids, and apoptosis (4). Due to their high need of 
bioenergetics, mitochondria are enriched at presynaptic and postsynaptic terminals of 
neurons (4).  
One of the most common mitochondrial defects that lead to neurodegeneration is 
oxidative stress. Mitochondria produce ATP through the oxidation of metabolic 
intermediates generated during Krebs cycle (8). ATP is generated by electron transport 
chain (ETC) via redox reactions across the inner mitochondrial membrane. Cells can 
defend themselves against those reactive oxygen species (ROS), produced during redox 
reactions, by several antioxidant enzymatic activities including superoxide dismutase 
and glutathione peroxidase; or scavengers including ascorbic acid (vitamin C), β-
carotene, ubiquinone, lipoic acid and tocopherol (vitamin E) (9). However, disturbances 
in the regular redox state of the cells might cause increased ROS. The resulting 
increased ROS production and insufficiency of antioxidant defense mechanism is called 
oxidative stress (10). Neuronal tissue is particularly more vulnerable to oxidative stress 
and damage; moreover, brain contains relatively low levels of antioxidants which lead 
to neurodegeneration (10). For example, PINK1 encodes a serine/threonine kinase 
located in mitochondria. Mutations in this gene causes early onset Parkinson’s disease 
due to stress induced degeneration of dopaminergic neurons (11).  
Beside oxidative stress, other major defects in mitochondria that lead to 
neurodegeneration are abnormal mitochondrial trafficking, distorted inter-organellar 
communication, and damaged mitochondrial quality control (4). SOD1 mutations 
induce mitochondrial membrane damage, discharging mitochondrial membrane 
potential and leading to ALS (11). Several other neurodegenerative diseases including 
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Parkinson’s disease, Alzheimer’s disease and Huntington’s disease are known to be 
caused by alterations or dysfunction in mitochondrial dynamics (12).  
1.2.3 Endoplasmic reticulum stress 
Endoplasmic reticulum (ER) is an important organelle for protein synthesis, 
folding, post-translational modification and transport (13). Accumulation of misfolded 
proteins and changes in calcium homeostasis lead to ER stress due to the loss of ER 
integrity or normal function. In order to restore the effects of ER stress, unfolded 
protein response (UPR) is activated by changing the expression of ER chaperones and 
enhancing degradation of misfolded or aggregated proteins. Sustained ER stress can 
lead to the activation of cell death pathways (13).  
The defects in the cellular processes involving ER cause different degrees of ER 
stress contributing to neurodegenerative disorders such as Alzheimer’s disease, 
amyotrophic lateral sclerosis, Parkinson’s disease, PolyQ diseases such as Huntington’s 
disease, and transmissible spongiform encephalophaties (TSE), or prion disease (13-18).  
1.2.4 Axonal transport deficits 
Motor neurons are large polarized cells. Their function is dependent on the 
intracellular transport of molecules along their axons. Anterograde axonal transport 
(towards the axon tip) carries proteins and lipids to the distal synapse and mitochondria 
(19). Retrograde transport (away from the synapse towards the soma) is essential for the 
clearance of defective proteins from the axon (19). Kinesin and dynein complexes are 
responsible for the axonal transport of cargoes in the anterograde and retrograde 
direction, respectively.  
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Defects in axonal transport are common factors in many neurodegenerative 
disorders. In Alzheimer’s disease, mutant presenilin 1 and amyloid-β impairs cargo 
attachment to kinesins and damages axonal transport (20, 21). Mutations in heat shock 
factor binding protein 1 (HSBP1) cause microtubule deacetylation and disruption of 
neurofilament assembly resulting in Charcot-Marie-Tooth disease (22). More than 40% 
of pure hereditary spastic paraplegias (HSPs) occur due to mutations in spastin (SPG4) 
which results in a progressive axonopathy affecting the cortiospinal tract (23). In ALS, 
mutations in dynactin 1 (DCTN1) protein harm microtubule-based axonal transport 
(24). The most common cause of ALS occurs due to the mutations in superoxide 
dismutase (SOD1). Mutant SOD1 together with glutamate inhibits cargo from binding 
to the motor protein which slows axonal transport (25).  
1.2.5 Environmental factors 
Acute or chronic exposure to environmental toxins can also cause 
neurodegeneration. Lead poisoning is one of the most common examples which cause 
myelin loss and axonal degeneration. Other metals (mercury, aluminum, zinc), 
pesticides, electromagnetic fields, brain injuries, inflammation, lifestyle and dietary 
factors are also associated with the increased risk of neurodegenerative disorders (26).  
Currently, there is no cure for neurodegenerative diseases, but the medications 
aim to ease the symptoms. The advances in technology allow the identification of new 
disease causing genes every day, which results in the exploration of common pathways 
that lead to certain neurological disorders. This will allow the development of new 
targeted therapeutic approaches for these pathways.  
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1.3 Disease Gene Identification Strategies  
As discussed in section 1.2., neurological disorders are influenced by both 
defective genes and environment. Identification of genes responsible for diseases is the 
first step to understand the human genome, to understand the pathophysiology of the 
disease, and the role of underlying proteins and pathways (27).  
1.3.1 Traditional Methods 
The most commonly used technique for the identification of Mendelian disease 
genes have been positional mapping through linkage analysis (28). Prior biological or 
medical knowledge is not needed to perform linkage analysis; therefore it is unbiased.  
The theory behind linkage analysis was developed by Thomas Morgan in 1910 that 
traits that are co-inherited are likely to be due to “factors” that are “linked” (29). Genes 
located in close proximity on a chromosome are less likely to have recombination 
events between them, and they tend to co-segregate together. Based on this, the first 
genetic map to estimate the distance between trait-causing genes based on 
recombination was created. If the two traits are co-segregated in a family, then they are 
assumed to be linked (30). Logarithm of odds (LOD) analysis compares the probability 
of obtaining the observations if the two loci are linked, to the probability of observing 
the same data by chance (30). For Mendelian disorders, a LOD score greater than 3 
suggests linkage. In 1977 spinocerebellar atrophy (SCA1) became the first 
neurolodegenerative disorder linked to a chromosome (HLA region of chromosome 6) 
(31). Later, in 1983, Huntington’s disease became the first neurologic disorder mapped 
to a genomic locus using polymorphic DNA markers (32). Although this technology 
allowed the identification of ~3,000 Mendelian disease loci (28), this approach yields 
only regions of linkage and not the causative gene.  
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The discovery of DNA sequencing through chain termination of 
dideoxynucleotides (ddNTPs) by Frederic Sanger in 1977 was a breakthrough in 
genomic technologies. This approach allowed the sequencing of candidate genes 
identified through positional mapping, and had been the most widely used sequencing 
technique for approximately 30 years (33). Nevertheless, identification of the genes 
present in the mapped region required several labor-intensive steps, such as cloning the 
region, and then determining the disease causing gene. For example, although 
Huntington’s disease was the first neurodegenerative disorder mapped to a certain locus, 
it took 10 years of research to clone the region and identify the disease causing gene 
(34). Medium-throughput DNA sequencing through automated capillary electrophoresis 
allowed the identification of human reference genome during the Human Genome 
Project from 1990 to 2001. This development eased the identification of disease causing 
mutations by eliminating several steps of cloning that required several years of research. 
However, even with the human reference sequence, most of the disease causing genes 
remained elusive due to large linkage regions containing hundreds of genes, which 
increased the costs of follow-up sequencing projects (35).  
In addition to linkage analysis, homozygosity mapping is another powerful 
method to identify recessive disease genes by identifying homozygous regions shared 
by the affected family members when the family is either consanguineous or practice 
endogamy (36). This technique relies on genome wide single nucleotide polymorphism 
(SNP) arrays of affected and unaffected family members.  
Despite these advances in technology, a particular category of diseases remained 
largely unsolved: rare genetic disorders due to the limited number of family members, 
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or diseases with de novo events, locus heterogeneity, reduced penetrance or variable 
expressivity.  
1.3.2 Whole Exome Sequencing 
Since 2005, next generation sequencing (NGS) platforms become available and 
reduce the cost and time of whole genome sequencing. NGS platforms are also applied 
to target the protein coding regions of the genome (known as the “exome”) through 
sequence capture by hybridization and massively parallel sequencing (Figure 1.1A). 
This allows the sequencing of the best known ~1% of the human genome which is 
estimated to hold ~85% of the mutations associated with disease phenotypes (28). 
Currently, the cost of whole exome sequencing technology is reduced to ~$600. 
Discovery of Mendelian disease genes through exome sequencing has been growing 
exponentially since it was first demonstrated in 2009 (37). Ongoing gene identification 
reveals genetic causes underlying neurological disorders and illuminates new 
biochemical pathways.  
Whole exome sequencing has successfully been applied for the identification of 
disease causing mutations in rare Mendelian diseases such as brain malformations, 
many forms of cerebellar ataxia and spastic paraplegia (38-40). Along with rare 
Mendelian diseases, whole exome sequencing has also been applied to common and 
complex disorders to identify highly penetrant variants in familial forms of Parkinson’s 
disease, Alzheimer’s disease, essential tremor, and multiple sclerosis (41-44).  
The main steps required for whole exome sequencing are shown in Figure 1.1A. 
Genomic DNA is randomly sheared into 200-300 bp by sonication. The ends of the 
fragments are converted into blunt ends by removing 3’ overhangs and filling 5’   
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Figure 1.1 Workflow of exome sequencing. (A) Isolated genomic DNA is randomly sheared 
into 200-300 bp followed by end repair, A-tailing and indexed paired-end adapter ligation. 
Exomes are captured and hybridized to biotinylated capture probes, and finally libraries are 
sequenced. (Copyright 2012 Nature Publishing Group. From Bras et al (35) with permission) 
(B) Flowchart of exome data analysis and variant filtration.   
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overhangs. Then the 3’ ends of the fragments are adenylated (A-tailing). Corresponding 
thymine nucleotide on the 3’ end of the adapters is ligated to the complementary 
fragment. DNA fragments with adapter on both ends are amplified by PCR. The 
resulting exome library is hybridized to biotinylated DNA beads. The captured DNA is 
amplified by PCR and is sequenced (Figure 1.1A).   
Whole exome sequencing generates millions of short sequence reads per run and 
the main challenge of whole exome sequencing is to make sense of the large amount of 
data. Identification of disease genes requires several steps of analytical and functional 
filtering and analyzing the data to sort through thousands of variants that differ from the 
human reference sequence (Figure 1.1B). The first analytical step after receiving whole 
exome sequence data is to map the millions of short sequences to a reference human 
genome. This is obtained from the reference assembly formed by the Human Genome 
Project. In order to detect the regions differ from the reference human genome, 
overlapping reads are required with a minimum coverage of 8 reads for heterozygous 
genotype calls and 4 reads for homozygous calls. A minimum of 30 reads per base is 
generally needed throughout the genome to reach the ideal depth of sequencing. Since 
sequencing platforms have error rates, it is important to differentiate the true variants 
from sequencing artifacts (45). In order to detect the variants that are rare or private to 
the subject, variants present in public databases (dbSNP, 1000genomes, EVS, or a set of 
unaffected individuals) are filtered out. During this filtration, the threshold for minor 
allele frequency (MAF) should be set accordingly. The next step is the functional 
filtering where detection of the functional variants among neutral coding variants is 
needed. Nonsense mutations and frameshift insertions and deletions resulting in a 
premature stop codon generally lead to truncated and usually nonfunctional protein 
products. In addition, several computational tools are used to predict the impact of 
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missense variants on protein function, such as SIFT, PolyPhen2, and MutationAssessor, 
in order to distinguish pathogenic variants from neutrals (46-48). These tools use 
biochemical properties of amino acid changes and multiple sequence alignments to 
obtain the degree of conservation among aminoacid residues in closely related 
sequences. Finally the candidate variants are verified by genotyping or capillary 
sequencing, and segregation status is analyzed if the family members are available.  
Now exome sequencing becomes the de facto approach to identify disease 
causing mutations. Although whole exome sequencing has increased the disease gene 
identification rate, there are still some major reasons why one can not find a variation 
associated with the disease. These are the lack of or poor sequence coverage of the 
coding regions, false negative calls in regions with poor quality sequence data, 
mutations in non-coding regions, and misinterpretation of missense variants (49). 
Whole genome sequencing and new prediction methods have been used to increase the 
success rate of disease gene identification.  
1.4 Consanguinity  
Individuals related as second cousins or closer are defined as consanguineous 
(50). The most common consanguineous marriages occur between first cousins. Since 
spouses share 1/8 of their genome, their progeny are homozygous for 1/16 of all loci. 
Consanguineous marriages are culturally favored in some countries, such as North 
Africa, West Asia and South India, and constitute around 20-50% of all marriages (51) 
(Figure 1.2). Consanguineous marriage rate in Turkey is around 20%.   
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Figure 1.2 Global prevalence of consanguinity. (http://www.consang.net with permission from 
A.H. Bittles) 
Consanguineous marriages have detrimental health effects as it increases the 
probability of disease causing mutations to reside in homozygous regions (52). 
Consanguineous populations have limited gene pool by founder effect; moreover, the 
risk of observing recessive phenotypes due to two copies of the same mutation is 
increased. A genomic region is classified as identical by descent (IBD) if contiguous 
SNPs share the same genotype in the family members. The IBD regions shared by all 
affected individuals that differ from the unaffected individuals are considered as disease 
causing region. Availability of high-density genome-wide SNP genotyping panels ease 
to trace IBD regions by analyzing the shared homozygous regions in consanguineous 
families with recessive disorders. (53). This can lead to the identification of founder 
mutations in isolated populations. In addition, consanguineous marriages may also 
introduce individuals with common disorders with a much severe phenotype due to 
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homozygosity; therefore, allows the identification of causative dominant mutations with 
dosage effect (54).  
1.5 Outline of the Thesis  
In this dissertation, my work on the genetic analysis of neurodegenerative 
disorders is divided into four chapters, including this introductory section.  
The second chapter addresses my work on the analysis and characterization of a 
family segregating essential tremor and Parkinson’s disease. Essential tremor is one of 
the most frequent movement disorders of humans, but its causes remain largely 
unknown. In a six-generation consanguineous Turkish family with both essential tremor 
and Parkinson’s disease, we identified a rare missense mutation of HTRA2 as the 
causative allele. Family members homozygous for this allele were more severely 
affected than those heterozygous for this allele. The same mutation had previously been 
associated with Parkinson’s characteristics in mouse mutants and with Parkinson’s 
disease in some, but not all, epidemiologic studies. Our results suggest that HTRA2 
might be responsible for essential tremor in some families and that homozygosity for 
damaging alleles of HTRA2 may be responsible for Parkinson’s disease.  
The third chapter covers the genetic analysis of a family segregating Troyer 
syndrome. We identified a consanguineous Turkish kindred with two affected siblings 
presenting clinical features similar to that of Troyer syndrome. Affected siblings have a 
novel missense mutation in SPG20. Frameshift mutations in SPG20 resulting into loss 
of function of spartin protein had previously been identified in Troyer syndrome 
patients. The clinical examinations showed that affected individuals in the Turkish 
family lack skeletal abnormalities observed in Amish and Omani populations with loss 
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of function mutations in SPG20. These findings suggest that truncated mutations in 
SPG20 cause a much severe phenotype than that of missense mutations, which indicates 
a genotype phenotype correlation. 
The final chapter summarizes my research and offers future perspectives on the 
genetic and molecular analysis of neurodegenerative disorders, and applications of these 
findings to clinical medicine. 
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Chapter 2 
2 Mitochondrial serine protease HTRA2 
p.G399S in a kindred with essential 
tremor and Parkinson’s disease 
The majority of the work described here was published in: Unal Gulsuner H., Gulsuner S., 
Mercan F.N., Onat O.E., Walsh T., Shahin H., Lee M. K., Dogu O., Kansu T., 
Topaloglu H., Elibol B., Akbostanci C., King M.-C., Ozcelik T., Tekinay A.B. 
“Mitochondrial serine protease HTRA2 p.G399S in a kindred with essential tremor and 
Parkinson disease”, Proc Natl Acad Sci USA, 2014, doi: 10.1073/pnas.1419581111 
2.1 Outline  
Essential tremor is one of the most frequent movement disorders of humans and 
can be associated with substantial disability. Some but not all persons with essential 
tremor develop signs of Parkinson’s disease, and the relationship between the conditions 
has not been clear. In a six-generation consanguineous Turkish kindred with both 
essential tremor and Parkinson’s disease, we carried out whole exome sequencing and 
pedigree analysis, identifying HTRA2 p.G399S as the allele likely responsible for both 
conditions. Essential tremor was present in persons either heterozygous or homozygous 
for this allele. Homozygosity was associated with earlier age at onset of tremor (P < 
0.0001), more severe postural tremor (P < 0.0001), and more severe kinetic tremor (P = 
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0.0019). Homozygotes, but not heterozygotes, developed Parkinson signs in the middle 
age. Among population controls from the same Anatolian region as the family, 
frequency of HTRA2 p.G399S was 0.0027, slightly lower than other European 
populations. HTRA2 encodes a mitochondrial serine protease. Loss of function of HtrA2 
was previously shown to lead to parkinsonian features in motor neuron degeneration 
(mnd2) mice. HTRA2 p.G399S was previously shown to lead to mitochondrial 
dysfunction, altered mitochondrial morphology, and decreased protease activity; but 
epidemiologic studies of an association between HTRA2 and Parkinson’s disease 
yielded conflicting results. Our results suggest that in some families, HTRA2 p.G399S 
is responsible for hereditary essential tremor and that homozygotes for this allele 
develop Parkinson’s disease. This hypothesis has implications for understanding the 
pathogenesis of essential tremor and its relationship to Parkinson’s disease. 
2.2 Introduction to Essential Tremor 
2.2.1 Tremor in human history 
Tremor is a rhythmic and oscillatory movement (55). This phenomenon was first 
recognized in ancient India (5000-3000 BC), Egypt (700 BC), and Greece (~400 BC) 
(56). There are also records of patients with kinetic and rest tremors in the writings of 
Galen of Pergamon (130-200 AD), Franciscus Sylvius (1680) and Gerard van Swieten 
(1745) (56). However, the first complete study was reported in 1887 by Dr. Charles 
Dana, with the presence of tremor in several large families (56).  
2.2.2 Clinical features 
Essential tremor (ET) is a progressive central nervous system disorder and is one 
of the most frequent movement disorders in humans (57). It is characterized by postural 
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or kinetic tremor of upper extremities, but head, legs, voice and other regions of the 
body may also be affected (58). Kinetic tremor occurs during voluntary movements 
such as drinking, eating or writing. The intentional tremor can be identified during a 
finger-to-nose movement if the amplitude of tremor increases when approaching to the 
target. Postural tremor might also occur in patients with essential tremor when they hold 
their arms horizontally against gravity. The familial forms of essential tremor show 
heterogeneity in terms of age at onset, rate of progression of tremor, and tremor 
distribution (59). Rest tremor, which occurs while a body part is relaxed and supported 
against gravity, has also been observed in patients with essential tremor (59). It is 
suggested that motor system abnormalities, such as basal ganglia, might cause the basis 
of rest tremor in essential tremor (58).  
Essential tremor is a slowly progressive disorder. Over the years, tremor might 
spread from the arms to the other unaffected body regions (58). Moreover, some 
essential tremor patients might develop Parkinson’s disease later in their lives (60). 
The worldwide prevalence of ET is 0.9%, increasing up to 4.6% in elderly 
populations (57). According to a population based study in Turkey, the prevalence of 
essential tremor is 4.0% among individuals older than 40 (61).  
2.2.3 Genetic heterogeneity 
ET is genetically heterogeneous (Figure 2.1). The first chromosomal region was 
mapped at chromosome 3q13 (ETM1; OMIM 190300) (62) in a genome-wide study 
including 16 Icelandic families with 75 affected individuals. ET was segregating in an 
autosomal dominant pattern. The logarithm of odds (LOD) score was 3.71; however, the 
highest single-family LOD score was 1.29, below the significant threshold to map a 
monogenic disorder to a marker. Common variant DRD3 p.S9G (OMIM 126451) 
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located in the ETM1 region has been proposed as a risk factor for ET (63) in 23 of 30 
French families, but this could not be replicated in other populations (64, 65). 
Therefore, these results should be taken cautiously.  
ETM2 (OMIM 602134) locus was mapped at chromosome 2p22-24 in a large 
American-Czech family segregating essential tremor in an autosomal dominant pattern 
with a significant LOD score of 5.92 (66). The same group confirmed the linkage to 
ETM2 lous in four independent American families (67). HS1BP3 p.A265G located in 
the ETM2 region was found in two families with ET (68). However, subsequent 
association and linkage studies were not able to identify any association or linkage to 
this region (69, 70). Thus the causality of ETM2 remains unknown.  
Linkage to chromosome 6p23 (ETM3; OMIM 611456) was identified in a 
genome-wide linkage study including seven American families with 325 affected 
individuals segregating ET in an autosomal dominant pattern (71). However, 
sequencing the 15 candidate genes in ETM3 locus did not identify any pathogenic 
variants. Two different linkage studies in Italian families with essential tremor excluded 
any linkage to ETM3 locus (70, 72). Genome wide association studies reported common 
intronic variants in LINGO1 (73) and in SLC1A2 (74) to be associated with ET, but 
meta-analysis indicated that it is unlikely that any of these variants are causative (75).  
Recently, a nonsense mutation p.Q290X in the RNA-binding protein FUS was 
identified by whole exome sequencing in a large family with ET (ETM4; OMIM 
614782) (43). Further screening of ET cases for FUS revealed two rare missense 
variants, (76, 77) suggesting that mutations in FUS explain a subset of cases of ET.  
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Figure 2.1 Genetic heterogeneity in familial essential tremor. Linkage studies revealed three 
genomic regions segregating with the condition. No clearly casual mutations have been 
identified in these regions, except two common variants associated with the disese. Recently a 
nonsense mutation in the RNA-binding protein FUS was identified by whole exome sequencing.  
Another study showed that DNAJC13 p.N855S, which had previously been 
identified in Parkinson’s disease patients, was also present in two unrelated patients 
with essential tremor (78). 
2.2.4 Etiologic and pathologic heterogeneity 
Disease etiology refers to the study of initial or primary causes and origin of the 
disease. The etiological studies showed that both genetic and environmental factors 
might be operating in combination for the cause of essential tremor (79). Environmental 
factors play a role in late-onset neurodegenerative disorders like essential tremor, 
Alzheimer’s disease and Parkinson’s disease. Case studies show that there are both 
familial and sporadic forms of essential tremor (58). The causes of these sporadic forms 
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of essential tremor are not fully known but β-carboline alkaloids and lead are some of 
the putative environmental factors that have been examined with several case-control 
studies (80, 81). β-carboline alkaloids are present in human diet, such as in animal 
proteins, and are found to be elevated in the blood concentration of essential tremor 
patients than in controls (80). Lead, a neurotoxin which causes cerebellar damage, has 
also been found to be higher in blood from essential tremor patients than controls (81). 
However, these studies need to be replicated with additional case-control studies. It is 
possible to suggest the “presence of a gene-environment or two-hit (increased genetic 
susceptibility followed by exposure to environmental factors) model” for essential 
tremor (59).  
Disease pathophysiology refers to the study of mechanisms operating within an 
organism and its changes after the disease occurrence. The pathophysiological basis of 
essential tremor is relatively unknown. The histopathological examinations of brains of 
indicated that essential tremor cases can be clustered into two categories: those with 
cerebellar degenerative changes and those with brainstem Lewy bodies (82). The 
majority of essential tremor cases have cerebellum with larger amounts of Bergmann 
glial cells and higher Purkinje cell axons, as well as other microscopic changes in the 
cerebellum (torpedoes) and have been referred as “cerebellar essential tremor” (Figure 
2.2A). Bergmann glial cells are nonspecific pathological response to injury, and 
torpedoes are swelling of the Purkinje cell axons which results in Purkinje cell loss (83). 
These findings are not unexpected since the tremor is believed to be mediated by 
cerebello-thalamo-cortical pathway (58). Moreover, the intentional component of 
essential tremor further supports an abnormality of cerebellar function (58). A smaller 
portion of essential tremor cases show Lewy bodies mainly in the locus coeruleus which 
is distinctive from brainstem   
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Figure 2.2 Pathological examination of the brains of patients with essential tremor. (A) 
Fusiformal axonal swelling (torpedoe) is observed on a modified silver stain of cerebellar 
Purkinje cell. Torpedoes are pathological accumulation of phosphorylated neurofilaments. (B) 
Haematoxylin-eosin staining of the locus coeruleus shows multiple Lewy bodies, with as many 
as four per neuron. (Copyright 2005 Elsevier. From Louis et al. (84) with permission) 
Lewy bodies where the patterns are observed prominently in substantia nigra pars 
compacta (84) (Figure 2.2B). This pattern is different from that of healthy and aged 
controls in whom Lewy body formation is not observed or very rare (82). It might be 
suggested that essential tremor patients who develop Parkinson’s disease in later ages 
go on to develop more widespread (such as nigral) Lewy bodies; however, further 
evaluation is needed.  
Therefore, it might be suggested that essential tremor is “a family of diseases 
rather than a single entity” (85) due to the presence of multiple genes and environmental 
factors as the cause for the disease, the evidence of variable pathologic patterns, and the 
broad variety in the clinical features. 
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2.2.5 Treatments 
There is no cure for essential tremor; however, some treatments can ease the 
symptoms for some patients (86). The cornerstone therapeutic drugs are anticonvulsant 
primidone and β-adrenoceptor antagonist propranolol (87). Deep brain stimulation 
(thalamic stimulation) is required to the patients who failed to benefit from the 
medications (88). Ethanol is also known to release the symptoms of tremor by binding 
to the GABAA receptors and facilitate GABAergic neurotransmission; however, there 
are also serious drawbacks of chronic alcohol usage for treatment (58).  
Identification of new causative genes for essential tremor will highlight new 
biochemical pathways to allow the design of new effective treatments.  
2.2.6 Aim of this study 
In this study, we examined a 6-generation family (ET-1) segregating ET or ET 
as a predominant feature of PD. We carried out whole exome sequencing of DNA from 
three severely affected individuals in the family in order to identify the causative 
mutation. 
2.3 Materials and Methods  
2.3.1 Subjects 
Family ET-1 is of Turkish origin. The proband was first evaluated at Ankara 
University Medical School. He and his informative relatives were followed at Ankara 
University Medical School and Hacettepe University Medical School. This project was 
approved by the ethics committees of all participating universities and informed consent 
was obtained from all individuals. Each participant was examined for essential tremor 
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using the criteria of both the Washington Heights-Inwood Genetic Study of essential 
tremor (WHIGET) and the Consensus Statement of the Movement Disorder Society 
(MDS) on Tremor (Table 2.1) (89, 90). Each participant was rated for rest and postural 
tremors and was asked to perform four different tasks (pouring water, drinking water 
from a cup, finger-to-nose movement, and drawing spirals) to elicit kinetic tremor. 
During the examination, severity of tremor was rated during each task (89). Participants 
were evaluated for features of Parkinson’s disease using the diagnostic criteria of the 
UK Parkinson’s Disease Society Brain Bank. Diagnosis of Parkinson’s disease required 
presence of bradykinesia plus at least one of muscular rigidity, resting tremor, or 
postural instability (91). We collected histories about distribution and severity of tremor 
and change of these parameters over time. Participants were interviewed about 
concurrent use of drugs that might cause action or resting tremor and for symptoms of 
hyperthyroidism, which was ruled out by TSH tests as needed. Clinical assessments 
were carried out by at least two neurologists without knowledge of participants’ 
genotypes. An additional 25 families with hereditary essential tremor, 59 patients with 
Parkinson’s disease, and 364 healthy controls, ages 20-30 and from the same central 
Anatolian region as family ET-1, were recruited for genetic analysis from Ankara 
University Medical School, Hacettepe University Medical School, and Bilkent 
University. Unaffected individuals showed no signs of disease at the time of 
examination. Because controls were young adults, they serve as population controls.  
2.3.2 DNA isolation 
DNAs of all family members were extracted from blood using Nucleospin Blood 
Kit (Macherey-Nagel) according to manufacturer’s protocol.  
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2.3.3 SNP genotyping, haplotype analysis and identity by descent analysis 
DNA samples from five affected subjects (IV:3, IV:4, IV:8, V:8 and VI:5) and 
one unaffected subject (IV:5) were genotyped using GeneChip mapping 250K NspI 
SNP arrays and analyzed using GTYPE software (Affymetrix).  
Identity by descent (IBD) regions shared by all genotyped affected family 
members were determined using a pipeline developed by King Lab (Figure B; Table B). 
SNP genotype data of a tio (unaffected mother (IV:5), affected father (IV:4), and 
affected daughter (V:8)) was used to determine the hypothetical disease alleles for each 
informative marker. Each marker was then compared in the additional three affected 
relatives (IV:3, IV:8, and VI:5). If genotypes of one of the three subjects is opposite 
homozygous at one marker (e.g. disease allele is A, opposite homozygous is BB) then 
this marker was called IBD0. Then, IBD0 SNPs were merged into segments to define 
IBD0 regions. A region was assigned as IBD0 if it contains at least 2 informative IBD0 
SNPs in a minimum 500 Kb segment. All IBD0 segments, centromeric and telomeric 
regions, and sequence gaps were filtered out from the whole genome. Remaining 
regions with at least 3 Mb in size were considered potential IBD segments.  
In order to determine whether essential tremor in family ET-1 is linked to 
DNAJC13 or to genomic regions previously reported to be associated with essential 
tremor (43, 62, 66, 71, 78), haplotype analysis were performed. Haplotypes were 
generated in a similar method used for IBD analysis to evaluate the possibility of a 
disease-causing mutation in any of these regions.  
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Table 2.1 Clinical characteristics of tremor in the affected individuals of family ET-1  
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 Tremor 
Archimedes 
Spiral Test 
Bradykinesia Rigidity 
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H
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Resting Postural Kinetic 
Head Chin Voice 
R L R L R L R L R L R L 
III:5 50 78 - + + ++ +++ +++ Yes No Yes +++ +++ - - + + - + 
IV:2 40 79 ++ + ++ ++ ++ ++ Yes No Yes +++ +++ + + - - - - 
IV:3 <30 81 - - ++ +++ ++ +++ No No No +++ +++ ++ ++ +++ ++ +++ ++ 
IV:4 <30 89 - - ++ +++ ++ +++ No No No +++ +++ ++ ++ +++ ++ +++ ++ 
IV:8 40 81 ++ + ++ +++ ++ +++ No Yes No ++ + +++ ++ +++ ++ + + 
IV:13 59 67 - - + ++ + ++ No No No + + - - + - - - 
IV:18 10 45 + + +++ +++ +++ +++ No Yes Yes +++ +++ - - - - - + 
V:3 48 56 - - + + + + No No No + + - - + - - - 
V:4 30 61 - + + + + + No No No + + - + + + - - 
V:6 50 60 - - + + - - No No No - - - - + - - - 
V:7 <55 59 - - ++ + + ++ No No No + + - - - - - - 
V:8 12 50 + + +++ +++ +++ +++ Yes No No +++ +++ - + - + - + 
V:9 15 56 + ++ ++ +++ + ++ No No No +++ ++ ++ + + + - + 
VI:5 10 25 - + +++ ++ ++ ++ No No No ++ ++ - - - - - + 
Abbreviations: For tremor +: low amplitude or barely perceivable tremor, ++: moderate amplitude tremor (1-2 cm), +++: large amplitude, severe tremor (>2 cm).(89) For 
Archimedes spiral test, bradykinesia, rigidity, postural instability and hypomimia +: mild, ++: moderate, +++: severe. R: right hand, L: left hand. None of the individuals had 
intentional tremor. Subject IV:9 was deceased and is not included in the table. Subject VI:5 was assessed based on his clinical history and is not included in the table. 
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2.3.4 Library construction and whole exome sequencing 
Three severely affected individuals (IV:3, IV:4 and VI:5) were selected for 
whole exome sequencing and their high quality DNA’s were isolated (Table 2.2).  
Table 2.2 Concentrations and qualities of DNA isolated for whole exome sequencing 
from ET-1 family 
Sample ID Concentration (ng/µl) A260/280 A260/230 
IV:3 215.7 1.9 2.0 
IV:4 252.1 1.9 2.2 
VI:5 131.5 1.8 1.7 
 
Library construction for whole exome sequencing was carried out according to 
manufacturer’s protocol (Illumina TruSeq DNA Sample Preparation Guide). For whole 
exome sequencing, DNA samples were diluted in suspension buffer to a final amount of 
2.5 μg in 55 μl. DNA was sheared into 200-300 bp for 120 s in sonicator at 6ºC 
(Covaris) in order to generate dsDNA fragments with 3’ or 5’ overhangs. The sheared 
DNA was run on a gel for quality check; the final amount of the sheared DNA should 
be 1 μg. End repair was performed in order to convert the overhangs resulting from 
fragmentation into blunt ends by incubating the fragmented DNA with End Repair Mix 
for 30 min at 30ºC. The fragmented DNA was cleaned up using AMPure XP Beads. 160 
μl AMPure XP Beads were added to each sample and this mixture was placed to 
magnetic stand. The DNA samples bound to beads were washed with 80% ethanol and 
dried. DNA was resuspended in Resuspension Buffer. This was followed by A-tailing 
by incubating the DNA fragments with A-tailing mix for 30 min at 30ºC. This reaction 
allows single ‘A’ nucleotides to be added to the 3’ ends of the blunt fragments to 
prevent them from ligating to one another during adapter ligation. Multiple paired-end 
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indexing adapters with corresponding T nucleotides on their 3’ ends were ligated to the 
complementary dsDNA overhangs by incubating at 30ºC for 10 min. The ligation 
reaction was inactivated by the addition of Stop Ligation Buffer. This step provided 
DNA fragments for hybridization onto a flow cell. The DNA fragments were cleaned up 
with AMPure XP Magnetic Beads. After this, DNA fragments with adapters on both 
ends are amplified with PCR. DNA quality was checked at this step by running on 
Agilent Technologies 2220 TapeStation instrument. Exomes were captured by SeqCap 
EZ Exome v2 (Roche) and hybridized to biotinylated capture probes at 47 ºC for 72h. 
The post-captured exomes were amplified with LM-PCR. The amplified captured 
exomes were cleaned up using Qiagen QIAquick PCR Purification Kit, and the final 
concentration and quality were calculated by running on Agilent D1K ScreenTape and 
analyzing with Agilent Technologies 2220 TapeStation software (Figure 2.3). Libraries 
were sequenced on an Illumina HiSeq2500. 
2.3.5 Bioinformatics 
Paired-end sequence reads were aligned to the human reference genome (hg19) 
using Burrows-Wheeler Aligner (BWA, v0.6.1-r104) (92). Removal of PCR duplicates, 
sorting and indexing were done using SAMtools v0.1.18 (93). Indel realignments and 
base quality score recalibration (BQSR) were done with Genome Analysis Tool Kit 
(GATK, v3.0-0-g6bad1c6) using recommended parameters (94). Genotypes were called 
and filtered using GATK Unified Genotyper and Variant Filtration tools. Variants were 
annotated using our in-house pipeline. Common SNPs and artifacts were excluded using 
dbSNP v138, the NHLBI Exome Sequencing Project, the 1000 Genomes Project, and 
700 exomes previously sequenced in our lab. Variants were defined as potentially 
damaging if they led to premature stop codon or were mutations with scores on in silico 
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prediction tools SIFT P≤  0.05, PolyPhen2 score ≥  0.8, and MutationAssessor score ≥  
1.95 (Table S2) (46-48).  
2.3.6 Sanger sequencing 
Genotypes for candidate variants for 24 informative relatives of family ET-1 
were determined by capillary sequencing (ABI 3130xl Genetic Analyzer). All coding 
regions, potential regulatory regions and miRNA binding sites of HTRA2 were 
sequenced in probands from 25 unrelated families with multiple relatives with essential 
tremor. Primers were designed using Primer3 (Table C1) (95). Products were analyzed 
via gel electrophoresis and Sanger sequenced. Sanger traces were analyzed with 
CLCBio Main Workbench software package (CLCBio Inc.). Family ET-1 was 
genotyped with FAM- and HEX- labeled primers for polymorphic markers on 
chromosome 2 flanking HTRA2 (ABI 3130xl Genetic Analyzer). Data was analyzed 
with GeneMapper v4.0 software package (Applied Biosystems).  
2.3.7 Population screening 
TaqMan genotyping assay (Life Technologies) was used for screening HTRA2 
p.G399S in Parkinson’s disease patients and controls. Custom TaqMAn SNP 
genotyping assay was designed to amplify and detect both alleleles with probes labeled 
with FAM or VIC dyes. One homozygous, one heterozygous, two no template controls 
and 364 Turkish control DNA samples (10 ng each) were added into each well of 384 
optical plate. TaqMan Universal PCR Master Mix (No AmpErase UNG) (2X) and SNP 
Genotyping Assay (20X) were mixed into the required volume and added into the each 
well of 384-DNA reaction plate. The reaction was performed on ABI 7900HT Fast   
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Figure 2.3 Quality control of post captured amplified whole exome library. (A) Gel image of 
post-captured DNA library. 1500 bp and 25 bp are intrinsic upper and lower markers, 
respectively. (B) Histogram representation of the results from panel A. bp: basepair, M: marker.  
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Real-Time PCR System with optimized conditions. After PCR amplification, an allelic 
discrimination plate read was set and performed, and the automatic allele calls were 
converted into genotypes (Figure D).  
2.3.8 Linkage analysis 
A LOD score for linkage of HTRA2 to essential tremor in the ET-1 family was 
calculated using LINKAGE v6.0 (96) under an autosomal dominant mode of 
inheritance with penetrance for homozygous or heterozygous genotypes of 1.0 at age 40 
and older and 0.6 before age 40, no phenocopies, and a mutant allele frequency of 0.01 
in the general population.  
2.3.9 Statistical analysis 
Statistical significance was evaluated by one-way analysis of variance 
(ANOVA), or analysis of covariance (ANCOVA), as appropriate.  
2.4 Results  
2.4.1 Clinical features of the ET-1 family 
The family is from central Anatolia, where consanguineous and endogamous 
marriages are common practice. Ancestors of the extended family have lived in the 
same area for more than 400 years. Essential tremor is known to have segregated in the 
family for generations. Twenty-four individuals from the family were clinically 
assessed (Figure 2.4). Sixteen family members showed varying degrees of tremor 
(Table 2.1; Figure 2.5), eleven of whom were diagnosed with ET and five of whom 
(IV:2, IV:3, IV:4, IV:8 and V:9) were diagnosed with ET co-existing with PD. 
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Figure 2.4 Pedigree of family ET-1 segregating essential tremor, with genotypes at HTRA2 G399S. Pedigree of family ET-1.Arrow indicates the proband. 
Individuals with ET are shown with filled black symbols, and with PD are shown with filled red symbols. Age at onset for affected individuals, and current 
ages and genotypes are indicated under the symbols. Individuals who underwent exome sequencing (IV:3, IV:4, VI:5) are represented with asterisks. V 
indicates the variant allele (Ser) at HTRA2 G399S; N indicates the wildtype allele (Gly). V:11: declined clinical examination.  
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Diagnoses of ET co-existing with PD were made as follows. IV:3 (age 81), IV:4 (age 
89), and V:9 (age 56) developed mild to moderate postural and action tremor before age 
30 and bradykinesia, rigidity, resting tremor, and postural instability with increasing 
age. IV:2 (age 79) developed postural and action tremor at middle age and subsequently 
bradykinesia and resting tremor. IV:8 (age 81) developed postural and action tremor at 
middle age and subsequently resting tremor, bradykinesia, rigidity, and postural 
instability. For all five of these patients, all the indicated signs were apparent upon 
physical examination for this study. Subject V:8, whose clinical features were 
particularly severe, was diagnosed with ET at age 12 and with Hashimoto’s thyroiditis 
at age 49. Subject IV:13 was using propranolol at the time of examination. Subjects V:3, V:4, 
V:6 and V:7 had mild tremor of at least 4 years’ duration. VI:4 has mild tremor with an age 
at onset of 24 according to his medical history, but his clinical scores could not be 
obtained by a face-to-face physical exam. Subject IV:9 provided a DNA sample but 
died before clinical evaluation; according to her clinical history she had mild hand and 
head tremor. Subject V:11 agreed to provide a DNA sample but declined subsequent 
clinical evaluation. Ages of onset of tremor ranged from ~10 years to 60 years. Some 
family members with tremor were not able to determine the exact age of onset as their 
tremor developed over many years. ET appeared to be inherited as an autosomal 
dominant trait spanning six generations. 
2.4.2 Gene discovery 
Results of exome sequencing of three severely affected relatives, IV:3, IV:4 and 
VI:5, are summarized in Table 2.3. The proportion of targeted genomic regions covered 
at least 8-fold was 95.1% for IV:3, 95.4% for IV:4, 94.6% for VI:5, and 93.6% jointly 
(Figure E1). Given that the kindred includes multiple consanguineous marriages, we 
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first considered the possibility of recessive inheritance of essential tremor as the result 
of homozygosity for a critical mutation that was identical by descent from a common 
ancestor. To evaluate this possibility, we identified homozygous genomic regions 
greater than 1 MB shared by the three affected relatives. There were three such regions, 
on chromosomes 2p13.1-p12 14q32.13, and 22q11 (Table 2.4). We then identified, in 
each of these regions, all variants predicted to be damaging (see Methods). The only 
potentially damaging variant was HTRA2 p.G399S (c.1195G>A, NM_013247) at 
chr2:74,759,825 G>A (rs72470545). HTRA2 p.G399S was predicted to be damaging by 
bioinformatics prediction tools Polyphen2 (score 0.986), SIFT (P = 0.02) and 
MutationAssessor (score 2.39).  
We next genotyped HTRA2 p.G399S in all family members. Of the 16 
individuals with essential tremor in the family, five were homozygous and 11 were 
heterozygous for the variant (Figure 2.4). The occurrence of both heterozygotes and 
homozygotes for the mutation among affected relatives precluded recessive inheritance 
via identity by descent. On the other hand, genotypes of the family were consistent with 
dominant inheritance of essential tremor due to this allele, possibly with a dosage effect.  
In order to evaluate the kindred for the possibility of dominant inheritance of any 
mutation in the genome, we next identified all potentially damaging variants, whether 
heterozygous or homozygous, shared by the three affected relatives with exome 
sequence. Including HTRA2 p.G399S, there were 13 such variants, all missenses (Table 
2.5). We genotyped all 13 variants in all family members. The only variant segregating 
with essential tremor in the family was the HTRA2 allele (Figure 2.4; Table 2.5; Figure 
2.6). The LOD score for linkage of HTRA2 p.G399S under an autosomal dominant 
model of inheritance was 5.27.   
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Figure 2.5 Archimedes spiral tests of individuals of various ages and genotypes at HTRA2 
p.G399S. For all individuals R: dominant right hand, L: non-dominant left hand. 
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We next considered the possibility that affected family members heterozygous 
for HTRA2 p.G399S might carry a second damaging allele of HTRA2 on their other 
copy of chromosome 2. In order to evaluate this possibility, two tests were carried out. 
First, HTRA2 was fully sequenced in all family members. No rare variants other than 
p.G399S were identified. Second, to test the possibility of a critical non-coding 
regulatory mutation of HTRA2 shared by affected family members, extended (3.7 MB) 
haplotypes flanking HTRA2 were determined for all relatives using informative 
polymorphic markers (Figure 2.7). Subjects heterozygous for HTRA2 p.G399S did not 
share a second haplotype. We concluded that the possibility of a second pathogenic 
HTRA2 allele segregating in this family is extremely unlikely. We also evaluated and 
excluded the possibility of linkage of essential tremor to a mutation in any of the 
genomic regions previously reported to be associated with the disorder (Figure F). 
Several lines of evidence suggested that the number of copies of HTRA2 
p.G399S influenced severity of the phenotype. First, results of the Archimedes spiral 
test (89) suggested that severity of action tremor was influenced by both genotype and 
age (Figure 2.5). Second, homozygosity versus heterozygosity at HTRA2 p.G399S was 
significantly associated with age at onset of tremor (F = 28.99 [2, 24 df], P < 0.0001; 
Figure 2.8A). Mean ages at onset of tremor were 21.4 years and 41.3 years for subjects 
homozygous and heterozygous for the mutation, respectively. Third, homozygosity 
versus heterozygosity at HTRA2 p.G399S was associated with severity of both postural 
tremor (F = 18.68 [2, 17 df]), P < 0.0001; Figure 2.8B) and kinetic tremor (F = 9.24 [2, 
17 df]), P = 0.0019; Figure 2.8C).  
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Table 2.3 Results of whole exome sequencing of DNA from three severely affected 
relatives from ET-1 
 IV:3 IV:4 VI:5 
Total number of reads 82,905,251 88,364,432 83,032,868 
% of mapped reads 98.1% 98.3% 97.6% 
% of targeted bases covered ≥  8X 95.1% 95.4% 94.6% 
Joint coverage at ≥  8Xa 93.6% 
Average coverage 90X 101X 83X 
    
All coding variants 18,729 18,839 18,198 
Shared by all 3 exomes 11,639 
Rare variants
b
 129 
Predicted damaging to protein function
c
 13 
Co-segregation with ET in the family 1 (HTRA2 G399S) 
Abbreviations. 
a
Joint coverage was defined as fold-coverage for the least well-covered individual of the three samples. 
bFiltered by dbSNP138 common SNPs and MAF ≥  0.005 in EVS or 1000G variants, and proportion of 
variant reads ≥  0.35. Both heterozygous and homozygous variants were included. 
c
Truncating mutations, splice site mutations predicted to lead to altered transcripts, and missense variants 
with all of Polyphen2 score ≥  0.8, SIFT score ≤  0.05 and MutationAssessor score ≥  1.95 were defined 
as damaging. Both heterozygous and homozygous variants were included. 
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Table 2.4 Homozygous regions shared by three affected relatives  
Chr Start End Size (bp) All SNPs Rare potentially functional SNVs and indels
†
 
2 73,518,867 75,115,108 1,596,241 48 1 
14 94,912,799 96,157,331 1,244,532 41 0 
22 16,953,727 18,650,682 1,696,955 77 0 
Homozygosity mapping from whole exome data was performed using PLINK V1.07 with 200 kb 
minimum segment size (1). In the shared homozygous regions, 98% of all coding bases were sequenced 
at least 4X in at least one subject with average coverage of 76X.  
†
Alleles predicted damaging to protein function were of the following classes: truncating mutations; 
splice site mutations predicted to lead to altered transcripts; whole gene deletions; and missense variants 
with Polyphen-2 score ≥  0.8, SIFT score ≤  0.05 and Mutation Assessor score ≥  1.95. 
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Table 2.5 Damaging coding sequence variants shared by exome sequences of three severely affected relatives of family ET-1 
Chr Start Ref Var Gene Effect Genotype PPH2 SIFT MA Gerp EVS 1000G 
Subjects with tremor 
NN NV VV 
2 55,194,157 C T EML6 R1839C Het 0.998 0.022 2.25 6.17 - 0.0009 4 10 2 
2 74,759,825 G A HTRA2 G399S Homoz 0.986 0.020 2.39 3.99 0.0034 0.0023 0 11 5 
3 13,359,234 G A NUP210 R1871C Het 0.999 0.021 2.07 4.58 - - 11 5 0 
4 1,343,416 T C UVSSA L68P Het 1 0.001 3.02 4.98 - - 10 6 0 
6 13,306,697 A G TBC1D7 L243S Het 1 0 2.67 5.87 - - 9 7 0 
9 104,190,765 T C ALDOB E122G Het 0.997 0 3.36 5.87 0.0001 - 9 7 0 
9 135,203,279 C A SETX V1236F Het 0.868 0.003 1.95 4.82 - - 5 11 0 
12 52,284,475 C T ANKRD33 R124W Het 1 0.001 2.28 - 0.0005 - 11 5 0 
15 41,797,248 C T LTK R647Q Het 1 0 2.50 3.79 0.0003 - 11 5 0 
15 58,004,256 G A GCOM1 R675Q Het 0.999 0.036 1.99 2.79 - - 6 10 0 
15 90,328,681 G A ANPEP R935W Het 1 0.013 3.12 5.31 0.0009 0.0005 11 5 0 
17 31,098,168 T C MYO1D Y230C Het 0.998 0 3.48 5.82 0.0008 - 10 6 0 
19 48,565,262 G A PLA2G4C P417L Het 0.819 0.013 2.48 2.79 - - 9 7 0 
Abbreviations: Chr: chromosome, Ref: reference base, Var: variant base, PPH2: Polyphen2, MA: MutationAssessor, EVS: Exome variant server, 1000G: 1000 genomes 
project, V: variant allele, N: wildtype allele.  
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Of 59 other Turkish individuals with Parkinson’s disease, none carries HTRA2 
p.G399S. In 25 other Turkish families, each including multiple relatives with essential 
tremor, complete sequencing of HTRA2 did not reveal any damaging mutations. Of 364 
unrelated Turkish controls, two were heterozygous and none were homozygous for 
HTRA2 p.G399S, yielding an allele frequency of 0.0027, approximately the same as 
reported in a population of mixed European ancestry (Table 2.5). Of the two controls 
heterozygous for the allele, one was anonymous and the other had given permission to 
be re-contacted. The re-contacted control is presently 27 years old. Upon neurological 
exam, she had no signs of essential tremor. 
2.5 Discussion  
Whole exome sequencing of three severely affected relatives of family ET-1, 
with no prior hypothesis about a causal gene, revealed HTRA2 p.G399S as the only 
potentially damaging allele co-segregating with essential tremor in the extended 
kindred. Homozygosity versus heterozygosity for this allele was associated with earlier 
age at onset and increased severity of essential tremor. Homozygotes for the mutation 
expressed a more severe phenotype, including signs of Parkinson’s disease at middle 
age, which suggested a dosage effect for this allele. Among heterozygotes, variability in 
age at onset of tremor could be influenced by genetic or environmental modifiers or 
stochastic effects (59).  
HTRA2 encodes a serine protease of 458 amino acids that localizes to the inter-
membrane space of mitochondria (97). Upon an apoptotic stimulus, the HTRA2 protein 
is released from the mitochondria into the cytosol and binds to inhibitor-of-apoptosis 
(IAP) proteins in order to initiate apoptosis (97). HTRA2 proteolytic activity also 
triggers caspase-independent cell death (98).  
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Several lines of evidence suggest involvement of HTRA2 in Parkinson’s disease. 
HtrA2 p.S275C leads to loss of protease activity and to a motor neuron degeneration 
phenotype with ataxia, repetitive movements, and akinesis in mnd2 mice (99). In 
addition, HtrA2 knockout mice show parkinsonian features due to the loss of neurons in 
striatum (100). Based on these observations, Strauss and co-workers sequenced HTRA2 
in a series of German Parkinson’s disease patients and controls, and identified HTRA2 
p.G399S (the mutation of family ET-1) and HTRA2 p.A141S as associated with the 
disorder (Figure 2.9A) (101). They also identified HTRA2 in Lewy bodies of 
Parkinson’s disease patients (101). Their study suggested that HTRA2 p.G399S leads to 
loss-of-function, because both missense mutations (HTRA2 p.G399S and HTRA2 
p.A141S) led to mitochondrial dysfunction, altered mitochondrial morphology, and 
decreased protease activity, and HTRA2 p.G399S resulted in increased sensitivity to 
toxicity (101). A recent study of transgenic mice also suggested that HtrA2 p.G399S is 
a loss-of-function allele. In these experiments, mice over-expressing a wild-type allele 
of HtrA2 showed significant motor impairments, whereas mice over-expressing HtrA2 
p.G399S showed no difference compared to non-transgenic mice. (102).  
In order to experimentally evaluate a dosage effect for this allele, it would be 
ideal to compare animal models heterozygous and homozygous for HtrA2 p.G399S. 
These animals have not been developed, but a clue to a possible dosage effect appears 
from the comparison of wildtype, HtrA2
+/-
, and HtrA2
-/-
 mice (100). Compared to wild-
type mice, HtrA2
+/-
 mice appear to show a subtle, though not statistically significant, 
decrease in performance on sensory-motor tests (100). Increasing the number of 
HtrA2
+/-
 mice in these experiments and extending their evaluation over a wider age 
range would provide valuable information on the possibility of a dosage effect for 
HTRA2 loss-of-function mutations.  
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Figure 2.6 Sanger traces of HTRA2 p.G399S in ET-1 family and its conservation. Sanger traces 
of individuals in ET-1 family and sequence homology of HTRA2 protein. (A) Sanger traces of 
an unaffected wildtype individual, an unaffected heterozygous parent, and an affected 
homozygous patient. The arrows show the mutation site. (B) Sequence homology of HTRA2 
protein among various species. 
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Figure 2.7 Haplotype structure at the HTRA2 locus for the ET-1 family. All participating family members were genotyped for six informative markers 
spanning 3.7 MB flanking HTRA2 and haplotypes constructed by direct pedigree analysis. The 12 subjects heterozygous for HTRA2 p.G399S harbor 9 
different haplotypes for their alternate allele, providing strong evidence against a second pathogenic mutation closely linked to HTRA2 
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Figure 2.8 Relationship between HTRA2 genotype and age at onset and severity of tremors of 
essential tremor. V indicates the variant allele serine and N indicates the wildtype allele glycine 
at HTRA2 p.G399S. Subjects heterozygous for the variant allele are indicated NV and those 
homozygous for the variant allele are indicated VV. (A) Essential tremor age at onset varies 
significantly by genotype, P < 0.0001. (B) Severity of postural tremor of homozygous and 
heterozygous subjects differs significantly; analysis of covariance by genotype with age at exam 
as covariate yields F = 18.68, (2, 17 df), P < 0.0001. (C) Severity of kinetic tremor of 
homozygous and heterozygous subjects differs significantly; analysis of covariance by genotype 
with age at exam as covariate yields F = 9.24, (2, 17 df), P = 0.0019.  
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Three other rare missense alleles, HTRA2 p.R36W, p.P143A, and p.R404W, 
were subsequently identified in patients with Parkinson’s disease (Figure 2.9A) (103-
105). HTRA2 p.A141S and p.P143A lie in close proximity to serine at residue 142, 
which is phosphorylated upon the activity of p38, dependent on PTEN-induced-
putative-kinase (PINK1) (Figure 2.9B) (106, 107). HTRA2 p.G399S and p.R404W lie 
in close proximity to serine at residue 400, which is phosphorylated upon activation of 
cyclin-dependent kinase-5 (CDK5) (106, 107). In transgenic mice expressing HtrA2 
p.G399S in cortex, phosphorylation at residue 400 was significantly reduced (107). 
Phosphorylation of HTRA2 at both sites is important for cellular stress response (107). 
Furthermore, PINK1 and CDK5 kinases are both known to be associated with 
Parkinson’s disease (108, 109). However, despite the biological plausibility of a role for 
HTRA2 in Parkinson’s disease, subsequent epidemiologic studies did not detect higher 
frequencies of any of the rare missense alleles of HTRA2 among Parkinson’s disease 
patients than among controls (103-105, 110).  
The role of HTRA2 in essential tremor may resolve this paradox. The individuals 
in family ET-1 who developed features of Parkinson’s disease exhibited these 
symptoms decades after onset of essential tremor. These included all three individuals 
homozygous for HTRA2 p.G399S and older than age 55, and two individuals 
heterozygous for HTRA2 p.G399S and older than age 78. These observations suggest 
that HTRA2 has a causal role in essential tremor and in the subset of essential tremor 
followed by Parkinson’s disease. Among essential tremor patients generally, the 
incidence of Parkinson’s disease is increased 4-to-5-fold, and essential tremor and 
Parkinson’s disease have previously been observed in the same families (111-113). We 
speculate that case-control studies of that subset of Parkinson’s disease preceded by 
essential tremor would reveal associations with functional missense alleles of HTRA2.   
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Figure 2.9 Schematic representation of HTRA2 protein and its activation against mitochondrial 
stress. (A) Localization of the previously identified mutations in HTRA2. Full length HTRA2 
consists of a putative transmembrane (TM) domain (aa 105-124), a conserved catalytic trypsin-
like serine protease (Tryp_SPc) domain (aa 178-342), and a C-terminal PDZ domain (aa 363-
445). (B) Oxidative stress results in the activation of p38 stress kinase pathway which 
phosphorylates HTRA2 to increase its proteolytic activity. p38 phosphorylates S142 in a 
PINK1-dependent manner; while S400 is phosphorylated by CDK5. Active HTRA2 induces 
stress-responsive caspases. PINK1 also recruits Parkin, E3 ubiquitin protein ligase, from cytosol 
to mitochondria to induce mitophagy. Red diamonds represent two potential phosphorylation 
sites at S142 and S400. P: phosphorylation.   
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Although essential tremor is one of the most common inherited neurologic 
disorders, identifying the responsible underlying genes has been challenging. 
Complexities of essential tremor include genetic heterogeneity, age-dependent 
penetrance, and variable expressivity, leading to difficulties both in differential 
diagnosis and in genetic analysis (59). Our results suggest that mutation of HTRA2 can 
be responsible for essential tremor in some families and that parkinsonian features may 
develop in these patients, after age 70 in heterozygotes and in middle age in 
homozygotes. These observations reveal one cause of essential tremor and may 
illuminate some of the shared features of essential tremor and Parkinson’s disease 
phenotypes. 
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Chapter 3 
3 A missense mutation in SPG20 cause 
Troyer Syndrome 
The majority of the work described here is in preparation for publication.  
3.1 Outline 
Hereditary spastic paraplegias (HSP) are neurological disorders with cardinal 
features of lower extremity spasticity and weakness. Troyer syndrome is an autosomal 
recessive complicated HSP caused by loss of function mutations in SPG20 gene. Here 
we report a consanguineous Turkish family with Troyer syndrome, where we identified 
a homozygous missense mutation p.G580R in SPG20 using whole exome sequencing of 
two affected siblings. This study indicates a phenotype-genotype relationship that 
although loss-of-function mutations cause Troyer syndrome, a similar phenotype 
without skeletal abnormalities was observed with a missense mutation in the same gene.  
3.2 Introduction to Hereditary Spastic Paraplegias 
3.2.1 Clinical and genetic features of Hereditary Spastic Paraplegias 
Hereditary spastic paraplegias (HSP) are characterized by progressive lower 
weakness and spasticity with a prevalence between 3 to 10 per 100,000 individuals 
(114). In addition to lower limb spasticity and weakness, which is observed in pure 
HSPs, other neurologic and non-neurologic abnormalities are observed in patients with 
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complicated HSPs; for example, intellectual disability, ataxia, peripheral neuropathy, 
distal muscle wasting, dementia, or optic neuropathy (115). The disease course shows 
extreme variability, including age at onset, presence of other symptoms, and the degree 
of weakness in the extremities.  
This variability in clinical presentation comes from the variability in the genetics 
of the disease. There are more than 70 genetic types of HSPs segregating with 
autosomal dominant, autosomal recessive, X-linked or mitochondrial inheritance 
patterns (115). HSP genetic loci are represented as SPG for spastic paraplegia. Among 
these disorders, SPG3A, SPG4, and SPG11 are relatively well understood due to a large 
number of patient sizes. The majority of HSPs have not been characterized in many 
families; therefore, their clinical features are not well known.  
The clinical features of HSPs overlap with many disorders. The differential 
diagnosis of HSPs includes abnormalities in the brain and spinal cord, leukodystrophy, 
some of the infectious disorders, other neurodegenerative disorders with motor neuron 
impairment, and environmental toxins (115). The symptoms of HSPs begin in early 
childhood and they remain relatively non-progressive even over several decades (116). 
The difficulties in diagnosis occur when there is no family history of similar 
characteristics, the durations of symptoms are too short to exclude other disorders, there 
are other neurologic abnormalities, and the genetic testing is not complete. 
Identification of a potentially pathogenic gene which has previously known to be 
causing HSP might be used to confirm the clinical diagnosis in a patient. There is no 
cure for HSPs; however, the resulting information from a genetic testing can be used for 
genetic counseling and prenatal/preimplantation genetic diagnosis.  
  
52 
 
Neuropathological studies suggest that HSPs are likely to occur due to 
degradation of the corticospinal motor neurons and axon degeneration (117, 118). The 
most important molecular mechanisms underlying the HSPs can be recruited from the 
58 identified genes up to date: axon transport (SPG30 [KIF1A], SPG10 [KIF5A], SPG4 
[Spastin], SPG20 [Spartin]), endoplasmic reticulum morphology (SPG3A [Atlastin], 
SPG4 [Spastin], SPG12 [reticulon 2], SPG31 [REEP1]), mitochondrial function (SPG13 
[chaperonin 60], SPG7 [paraplegin], mitochondrial ATP6), myelination (SPG2 
[Proteolipid protein], SPG42 [Connexin 47]), protein folding and degradation (SPG6 
[NIPA1], SPG8 [K1AA0196], SGP17 [BSCL2], SPG18 [ERLIN2]), vesicle transport 
and membrane trafficking (SPG47 [AP4B1], SPG48 [KIAA0415], SPG50 [AP4M1], 
SPG51 [AP4E], SPG52 [AP4S1], VSPG53 [VPS37A]), and lipid metabolism (SPG28 
[DDHD1], SPG35 [FA2H], SPG39 [NTE], SPG54 [DDHD2], SPG56 [CYP2U1]) (40, 
116). Exploring new genes related to interacting molecular pathways and their 
evaluation in animal models will allow the exploration of disease mechanisms and 
potential treatments. 
3.2.2 Troyer Syndrome 
Troyer syndrome (OMIM #275900) is classified as a complicated HSP inherited 
in an autosomal recessive fashion. The most common characteristics of Troyer 
syndrome are spastic paraparesis, distal amyotrophy, progressive muscle weakness, 
subtle skeletal abnormalities, mild developmental delay, learning disorders, dysarthria 
and mood swings. Other characteristics might include hyperreflexia, pseudobulbar palsy 
(119).  
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3.2.2.1 Previously Identified Families with Troyer Syndrome 
3.2.2.1.1 Old Order Amish 
Troyer syndrome was first identified in 1967 in three individuals with Old Order 
Amish origin in Ohio, USA (119). 18 additional individuals with Troyer syndrome in 
the same Amish population have been reported up to date (120). The Old Order Amish 
population practice endogamy and they have large families, which is suitable to study 
recessively inherited conditions. These individuals were from different families; 
however, all of them were traced back to a common ancestor. The ages of patients were 
between 2 and 63 years, and the most common feature they share was delayed walking 
and talking. Distal amyothropy was present in all individuals older than 13 years 
(except a 7 year-old patient). Learning difficulties, difficulty at school and emotional 
lability were also reported in the patients. Most of the patients had spastic dysarthria. 
The patients exhibited mild skeletal abnormalities including short stature, small feet 
with pes cavus, and hammer toes. Brain magnetic resonance images (MRI) showed 
white matter abnormalities in affected individuals.  
SPG20 c.1110delA frameshift mutation has been identified in two Amish 
families (121, 122). This frameshift mutation resulted in loss of protein expression in 
cells isolated from affected individuals (122).  
3.2.2.1.2 Omani 
Troyer syndrome was also described in two related Omani families. Their 
common symptoms were dysarthria and delays in motor and cognitive development, 
difficulties in walking, mild spastic gait, short stature and hand and foot abnormalities 
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including brachydactyly, hammer toes, and pes cavus (123). Similar to the Amish 
families, the patients of Omani family had poor performance in school.  
SPG20 c.364_365delAT mutation was identified as the cause of Troyer 
syndrome in the two related Omani families (123). This frameshift mutation also results 
into lack of expression of spartin protein (123). 
3.2.2.1.3 Other families with Troyer-like Features 
 A Kuwaiti and an Austrian family were reported with features similar to that of 
Troyer syndrome. However, sequencing SPG20 in both of these families did not reveal 
any damaging mutations which suggested a different genetic etiology (120, 124, 125).  
3.2.3 Aim of this study 
In this study, we report a family in which two of the three siblings exhibit 
several neurological symptoms similar to that of Troyer syndrome. Whole exome 
sequencing was performed to two affected siblings in the family in order to identify the 
causative mutation.  
3.3 Materials and Methods  
3.3.1 Subjects 
The family is of Turkish origin. The proband and his informative family 
members were evaluated at Hacettepe University Medical School. This study was 
approved by the ethics committees of all participating universities, and all individuals 
provided informed consent. 346 healthy controls from central Anatolian region of 
Turkey were obtained from Bilkent University for genetic analysis.  
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3.3.2 DNA isolation 
DNA of the affected subjects and relatives were extracted from blood using 
Nucleospin Blood Kit (Macherey-Nagel) according to manufacturer’s protocol. Two 
affected siblings (subjects IV:1 and IV:2) were selected for whole exome sequencing 
(Table 3.1).  
Table 3.1 Concentration and quality of DNA extracted from patients for whole exome 
sequencing from ET-4 family 
Sample ID Concentration (ng/µl) A260/280 A260/230 
IV:1 177 1.8 1.6 
IV:2 183.8 1.8 1.6 
 
3.3.3 Library construction and whole exome sequencing 
 Library construction and sequencing was carried out according to the 
protocols described previously (126). Briefly, the genomic DNA isolated from two 
affected individuals was randomly sheared into 200-300 bp fragments which is followed 
by end repair, A-tailing and indexed paired-end adapter ligation. Exomes were captured 
by SeqCap EZ Exome v2 (Niblegen, Roche), hybridized to biotynylated probes, 
amplified, and purified. DNA libraries were quality checked at this step by Agilent 2220 
TapeStation Instrument (Figure 3.1). Libraries were sequenced on an llumina 
HiSeq2500 platform.  
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Figure 3.1 Quality control of post captured amplified whole exome libraries of ET-4 family. (A) 
Gel image of post-captured DNA library. Purple and red lines are intrinsic upper and lower 
markers, respectively. (B) Histogram representation of the results from panel A. bp: base pair, 
M: marker. 
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3.3.4 Bioinformatics 
 Reads were mapped to the human reference genome (hg19) using Burrows-
Wheeler Aligner (BWA, v0.6.1-r104) (92). SAMtools v0.1.18 was used to remove PCR 
duplicates, sorting and indexing of the alignments (93). Indel realignments and base 
quality score recalibration (BQSR) were done with Genome Analysis Tool Kit (GATK, 
v3.0-0-g6bad1c6) (94). Genotypes were called and filtered using GATK Unified 
Genotyper and Variant Filtration tools. Variants were annotated using University of 
Washington King Lab’s in-house pipeline. Artifacts and common variants were 
excluded using dbSNP v138, the National Heart, Lung, and Blood Institute (NHLBI) 
Exome Sequencing Project, the 1000 Genomes Project, and 700 exomes previously 
sequenced in our lab. Missense variants were evaluated for their functional impact using 
SIFT (≤  0.05) (46), PolyPhen2 (≥  0.8) (47) and MutationAssessor (≥  1.95) (48) 
prediction tools.  
3.3.5 Sanger sequencing and population screening 
Candidate variants were genotyped in 14 informative family members by 
capillary sequencing to test for co-segregation. Primers were designed using Primer3 
(95) (Table C2). The PCR products were Sanger sequenced and Sanger traces were 
analyzed with CLCBio Main Workbench software package (CLCBio Inc.).  
3.3.6 Population screening 
TaqMan genotyping assay (Life Technologies) was used for population 
screening of SPG20 p.G580R in 346 healthy Turkish controls.  
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Table 3.2 Clinical characterization of ET-4 family and comparison with previously 
published studies 
Features IV:1 IV:2 Omani  Amish I Amish II 
SPG20 mutation p.G580R p.G580R c.364_365_delAT c.1110delA c.1110delA 
Age (y) 14 11 Mean 16.6 Mean 12.25 Mean 40.7 
Sex M F 
   
Height (cm) 154 139 Short Short Short 
% 10 10-25 
   
OFC (cm) 50.5 49 Normal Normal Normal 
% 50-75% 25-50% 
   
Weight (kg) 39 31 N/A N/A N/A 
Developmental milestones and cognition 
    
Talked at (y) 2.5 1.5 Late (100%) Late (87.5%) Late (80%) 
Walked at (y) 1 1 Late (67%) Late (87.5%) Late (80%) 
Poor school performance + + + (80%) + (100%) + (83.3%) 
Emotional lability - - - + (62.5%) + (92.3%) 
Neurological exam 
     
Dysarthria + + + (100%) + (100%) + (100%) 
Tongue dyspraxia + - + (80%) Often Often 
Distal amyotrophy - - + (67%) + (62.5%) + (100%) 
Hyperreflexia upper + + + (33%) + (12.5%) + (91.7%) 
Hyperreflexia lower + + + (67%) + (100%) + (100%) 
Ankle clonus - - + (50%) + (25%) + (44.4%) 
Clumsy, spastic gait + + + (100%) + (100%) + (100%) 
Dysmetria + + + (50%) + (62.5%) + (100%) 
Extensor plantar reflex + - N/A + (62.5%) + (81.8%) 
Tremor Action Action N/A N/A N/A 
Tremor onset (y) 4 4 N/A N/A N/A 
Skeletal Abnormalities 
    
Overbite - - + (100%) No No 
Hypertelorism - - + (83%) No No 
Hand/foot abnormalities - - + (100%) + (100%) + (100%) 
OFC: occipitofrontal circumference, N/A: not available. *clinodactyly, camptodactyly, hypoplastic 5th 
middle phalanges 
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3.4 Results  
3.4.1 Clinical features of the family 
The ET-4 family originates from the south-eastern Anatolia of Turkey. The 
proband (subject IV:1) was referred to Hacettepe University Medical School because of 
his severe action tremor at age 14 years. He was born at term with a birth weight of 3.2 
kg and head circumference of 35.5 cm. There was not any history of exposure to 
teratogens or infection during pregnancy. His initial developmental milestones were 
slightly delayed. He walked at age 12 months, and talked at age 30 moths. His tremor 
was first recognized at age of 4 years and slowly progressed over time. His tremor was 
very severe at the time of examination that he needed special help for his daily 
activities, such as eating and drinking. Physical examination upon the first visit revealed 
weight of 39 kg (90%), height of 154 cm (10%), and OFC of 50.5 cm (50-75%). 
Neurological examination showed moderate to severe tremor and clumsy, spastic gait 
with mild ataxia. He had dysarthria, tongue dyspraxia, hyperreflexia in upper and lower 
limbs, dysmetria, and positive Babinski sign (Table 3.2). He did not have any skeletal 
abnormalities (Figure 3.2). His IQ was 70. He could not attend to mainstream school, 
and was receiving special education. Brain MRI scans showed bilateral vermian 
cerebellar atrophy, bilateral cerebral symmetric hyperintensities and patchy signal 
hyperintensity in the pons in T2 weighted images (Figure 3.3A, B). His 11 year old 
sister (subject IV:2) was also similarly affected with age at onset of 4 for tremor. Her 
developmental milestones were normal compared to her unaffected sister. She had 
dysarthria, upper and lower hyperreflexia, dysmetria and action tremor (Table 3.2). Her 
MRI scans showed bilateral thalamic atrophy, bilateral posterior dominant 
periventricular and ventrolateral thalamic hyperintensities (Figure 3.3C, D). Both 
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patients were able to walk. They had a 4 year old healthy sibling. Their parents were 
first cousins. The mother’s first pregnancy product died in utero in the 6th week of 
gestation with no apparent cause.  
 
 
Figure 3.2 Morphological and radiological analysis of extremities of subject IV:1. Subject IV:1 
with Troyer syndrome does not have any foot (A, B) or hand (C, D) skeletal abnormalities. 
3.4.2 Gene discovery 
 The exome sequence data of two affected siblings were summarized in 
Table 3.1. Coverage of targeted genomic regions was 33.4X for IV:1 and 53.9X for 
IV:2 (Figure E2). Percent of targeted regions covered at least 4X was 94% for IV:1 and 
97% for IV:2. A detailed statistics about the results of exome sequence experiment is 
given at Table 3.3. Whole exome sequencing revealed 12 homozygous rare variants, 
three of which are damaging (Table 3.4; Table 3.5). All of these three mutations were 
segregating with the disease in ET-4 family. Among these genes, C17orf70 encodes a 
fanconi anemia associated protein (FAAP100) which is a component of fanconi anemia 
core complex (127). The fanconi anemia phenotype was ruled out by clinical 
examination of the patients. CSNK1A1L p.Q198K mutation was identified in a retro-
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gene originated from CSNK1A1 which is highly expressed in testis (RetrogeneDB). The 
third mutation was SPG20 (spartin) p.G580R at chr13:36,878,765 C>T (NM_015087). 
SPG20 p.G580R mutation was predicted to be damaging by prediction tools Polyphen2 
(score 1.0), SIFT (P = 0.0) and MutationAssessor (score 2.150) (Table 3.5). Based on 
the phenotypic overlap between families with SPG20 mutations and this Turkish family, 
we focused on SPG20 p.G580R mutation as the cause of Troyer syndrome in the 
kindred.  
SPG20 p.G580R mutation was inherited in an autosomal recessive fashion with 
the disease in the family (Figure 3.4A, B). The mutation lies in a highly conserved PDZ 
domain of spartin protein (Figure 3.5A, B). SPG20 p.G580 mutation was not detected in 
346 healthy Turkish controls 650 in-house exomes, and was absent from the population 
database, including dbSNP38, 1000 Genomes Project, NHLBI Exome Sequencing 
Project and ExAC V0.2. 
3.5 Discussion  
In this study, we report the third mutation identified in SPG20 in a Turkish 
family with Troyer syndrome. Loss of function mutations in SPG20 have previously 
been identified in two different populations with Troyer syndrome; Amish and Omani 
(122, 123, 128). After the characterization of the first Troyer syndrome cases in the 
Amish population, several Troyer-like syndromes have been identified in other 
populations (124, 125); however, sequencing of SPG20 in these families did not reveal 
any damaging mutations (120). We compared the clinical features of the individuals in 
the Turkish family with that of the previously reported Amish and Omani families with   
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Figure 3.3 Brain MRI scans of affected subjects. Thalamic atrophy (white arrows) and mild 
vermian cerebellar atrophy (arrowheads) of subjects IV:1 (A) and IV:2 (C) in axial T1 weighted 
MRI sequences. Bilateral periventricular posterior dominant hyperintensities (white arrows) of 
subjects IV:1 (B) and IV:2 (D) in axial T2 weighted MRI sequences. 
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Table 3.3 Results of whole exome sequencing of DNA from two affected relatives from 
family ET-4 
Fetures IV:1 IV:2 
Total reads 63,885,397 13,0874,348 
Average coverage 33 54 
% coverage at 4X 94 97 
% coverage at 20X 67 83 
Coding variants 19,410 19,617 
Shared by all 2 exomes 16,069 
Rare variants
a 240 
Homozygous in 2 exomes 12 
Predicted damaging to protein function
b 3 
Abbreviations. 
a
Filtered by dbSNP138 common SNPs and MAF ≥  0.001 in EVS or 1000G variants. 
b
Truncating mutations, splice site mutations predicted to lead to altered transcripts, and 
missense variants with all of Polyphen2 score ≥  0.8, SIFT score ≤  0.05 and MutationAssessor 
score ≥  1.95 were defined as damaging. Both heterozygous and homozygous variants were 
included. 
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Table 3.4 Homozygous rare variants shared by IV:1 and IV:2 
Chr Coordinate Ref Var Type Gene Protein cDNA PPH2 SIFT MA 
Reads (Total|Variant) 
IV:1 IV:2 
2 183,791,545 A G Missense NCKAP1 M1090T c.T3269C (exon30) 0.307 0.172 1.040 33 | 33 53 | 53 
2 242,684,234 C T Silent D2HGDH I131I c.C393T (exon5) - - - 29 | 29 51 | 51 
4 54,327,703 G A Silent LNX1 G554G c.C1662T (exon9) - - - 43 | 42 96 | 96 
4 54,244,053 G C Silent FIP1L1 G16G c.G48C (exon1) - - - 25 | 25 64 | 64 
6 135,265,012 C T Silent ALDH8A1 A77A c.G231A (exon2) - - - 23 | 23 26 | 25 
9 71,080,024 G A Missense PGM5 M353I c.G1059A (exon7) 0.257 0.015 1.245 48 | 48 76 | 76 
13 37,678,802 G T Missense CSNK1A1L Q198K c.C592A (exon1) 1.000 0.000 4.595 82 | 82 134 | 134 
13 36,878,765 C T Missense SPG20 G580R c.G1738A (exon9) 1.000 0.000 2.150 31 | 31 30 | 30 
17 79,511,038 G A Missense C17orf70 R807C c.C2419T (exon7) 1.000 0.000 2.210 13 | 13 24 | 24 
17 75,478,306 C T Missense SEPT9 R156W c.C466T (exon2) 0.997 0.002 1.795 9 | 9 19 | 19 
17 79,639,666 C T Missense CCDC137 R268W c.C802T (exon6) 0.996 0.016 1.320 17 | 17 23 | 23 
17 72,916,421 G C Silent USH1G A67A c.C201G (exon2) - - - 15 | 15 26 | 26 
Bold represents variants predicted to be damaging. 
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Table 3.5 Rare damaging variations identified in two affected siblings IV:1 and IV:2 
Chr Start Ref Var Gene Effect PPH2 SIFT MA EVS 1000G 
13 36,878,765 C T SPG20 G580R 1.000 0.000 2.150 - - 
13 37,678,802 G T CSNK1A1L Q198K 1.000 0.000 4.600 - - 
17 79,511,038 G A C17orf70 R807C 1.000 0.000 2.210 0.00007 - 
Abbreviations: Chr: chromosome, Ref: reference base, Var: variant base, PPH2: Polyphen2, 
MA: MutationAssessor, EVS: Exome variant server, 1000G: 1000 genomes project. 
 
 
 
 
 
 
 
 
 
  
  
66 
 
 
 
 
Figure 3.4 Pedigree of family ET-4 and segregation of the SPG20 mutation. (A) Pedigree of 
ET-4 family segregating Troyer syndrome, with genotypes at p.G580. Filled and unfilled 
symbols represent affected and unaffected individuals, respectively. N indicates the wildtype 
allele, glycine; and V indicates the mutant allele, arginine at SPG20 p.G580R. Individuals who 
underwent exome sequencing (IV:1 and IV:2) are represented with arrows. (B) Sanger traces of 
an unaffected wildtype individual, an unaffected heterozygous parent, and an affected 
homozygous patient. The arrows show the mutation site. 
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Figure 3.5 Spartin protein and its sequence homology among species. (A) Full length spartin 
consists of a microtubule-interacting and trafficking molecule (MIT) domain (aa 16-94), and a 
plant related senescence domain (aa 426-613). The positions of the mutations identified in 
spartin are shown. (B) Sequence homology of spartin protein. 
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with SPG20 mutations (Table 1). Up to date, 21 individuals with Troyer syndrome were 
reported from the same Old Order Amish population (120). The ages of patients ranged 
from 2 to 63 years. Since the symptoms of the Troyer syndrome worsens with age, we 
sub-grouped the affected individuals in the Amish population according to their ages: 
Amish I group (< 24 y, mean age 12.25 y), and Amish II group (≥  24 y, mean age 40.7 
y). The ages of Omani patients ranged from 4 to 27 years with mean age of 16.6 years. 
Table 1 clearly shows that individuals in Amish II group have the most severe 
phenotypes. The clinical features of the Turkish family resembles that of the age-
matched Amish I populations. The severity of the clinical features of Omani patients lie 
in between Amish II and Amish I populations, and is slightly severe than that of Turkish 
population. As opposed to Omani and Amish families, Turkish individuals do not have 
any skeletal abnormalities or distal amyotrophy. According to the reports, distal 
amyotrophy was not present in young subjects, and it was more severe in older cases 
(120, 123); which explains the lack of this symptom in the young Turkish individuals.  
SPG20 encodes a 666 amino acid spartin protein which is widely expressed in 
humans. It is a multifunctional protein consisting of a microtubule interacting and 
trafficking (MIT) domain and a plant related senescence domain (Figure 3.5). Spartin 
was reported to localize to several different cellular compartments such as neurites, 
endosomes, midbodies, lipid droplets (LDs), mitochondria, and trans-Golgi network in 
differentiated neurons (129-132). Spartin interacts with endosomal ESCRT-III protein 
IST1 with its MIT domain (131). The ESCRT-III complex is a major part of ESCRT 
machinery which enables membrane remodeling including multivesicular body (MVB) 
biogenesis and cellular abscission (131). In a cell, ubiquitin tagged misfolded or 
damaged proteins are located to MVBs, which fuse with lysosomes to destroy these 
proteins (133). When ESCRT machinery does not work properly, these damaged 
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proteins aggregate and lead to neurodegenerative disorders. SPG4 protein spastin also 
interacts with the ESCRT -III protein IST1 which suggests a shared role of ESCRT 
machinery in different forms of HSP. Spartin has a proline rich PPxY sequence motif 
which interacts with E3 ubiquitin ligases AIP4 and AIP5 (131, 134). Spartin also takes 
role in many different cellular processes including the endocytosis and transport of the 
epidermal growth factor receptor (EGFR), and cytokinesis (135).  
Several biochemical studies and experiments in model organisms have been 
performed to dissect the effect of mutations in SPG20 in HSP phenotype. Quantitative 
PCR and in situ hybridization analysis showed that Spg20 has its most specific 
expression in the limbs, face and forebrain during early morphogenesis which correlates 
with the phenotypic abnormalities observed in individuals with Troyer syndrome who 
lack spartin protein (123). Spartin protein is expressed in Turkish Troyer syndrome 
patients with SPG20 p.G580R mutations, which might explain the normal skeletal 
features observed in these patients. Spg20
-/-
 mice showed significant gait phenotype 
together with defects in axon branching in cerebral cortical neurons, LD maintenance, 
cytokinesis, and BMP signaling (136). These defects are associated with several Troyer 
syndrome abnormalities. The Troyer syndrome model in Drosophila showed that flies 
expressing mutant spartin have defects in the ability of climbing which was rescued by 
the neuronal expression of spartin (137). Moreover, aged adult spartin mutant flies 
displayed neurodegeneration which was found to be a cause of increased BMP 
signaling. BMP signaling is essential for neuronal development and distal axonal 
function (138). Defects in this pathway have previously been identified in some of the 
other HSP proteins, such as atlastin-1 (SPG3A), spastin (SPG4), and NIPA (SPG6) 
(138).  
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Spartin ortholog in C. elegans (F57B10.9) is expressed in the nervous system 
(wormbase). As a future study, phenotypic effect of p.G580R mutation in C. elegans 
will be evaluated. C. elegans have successfully been used as a model organism due to 
its simple genetics. Their transparent body makes the worm anatomy easily observable 
through light microscopy. Moreover, they are really easy to cultivate and genetically 
manipulate. Therefore, C. elegans is an ideal system to study the molecular bases of 
human diseases like HSPs.  
Our results show that Troyer syndrome might be caused by a missense mutation 
in spartin protein. The clinical findings in these three studies, including this study, 
suggest that Troyer syndrome starts with developmental abnormalities, has slow but 
definite progression which supports neurodegeneration. Further functional studies will 
be conducted in order to reveal the effects of p.G580R missense mutation in SPG20 
related biological pathways and BMP signaling. 
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Chapter 4 
4 Conclusion and Future Perspectives 
4.1 Research Summary 
In summary, this thesis focused on the genetic analysis of two clinically complex 
neurodegenerative disorders: Essential tremor, one of the most prevalent movement 
disorders; and Troyer syndrome, a very rare disorder with a highly severe phenotype. 
Whole exome sequencing with the following pedigree analysis identified causative 
mutations for both disorders. A genotype-phenotype correlation was shown in both 
diseases. The second chapter shows that individuals with heterozygous HTRA2 
p.G399S develop essential tremor with a mean age at onset of 40 y. On the other hand, 
in individuals with two mutant alleles, essential tremor tended to appear earlier in life, 
progressing to Parkinson’s disease when individuals reach middle age. The third chapter 
describes a family with Troyer syndrome with homozygous SPG20 p.G580R mutations. 
Loss of function mutations in SPG20 have already been known to cause Troyer 
syndrome with spastic gait, dysarthria, distal amyotrophy, mild developmental delay, 
learning disorders, and subtle skeletal abnormalities. Nevertheless, individuals carrying 
homozygous SPG20 missense mutations do not develop skeletal abnormalities.  
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4.2 Unraveling the genetic bases of complex 
neurodegenerative disorders 
Traditional strategies had identified many disease loci and genes; however, the 
genetic basis of complex neurodegenerative disorders remained to be elusive. Whole 
exome sequencing allows us to identify the causative mutations in previously 
undiagnosed or clinically complex conditions. The advantages of consanguineous 
families have been used for years to identify disease causing mutations through 
homozygosity mapping strategies. This leaded to the identification of hundreds of 
causative mutations for autosomal recessive disorders. The studies in this thesis showed 
that consanguineous families also help us to identify disease causing mutations for 
complex neurodegenerative diseases; i.e., consanguineous marriages introduce 
individuals with common disorders with a much severe phenotype due to 
homozygosity, allowing the identification of causative dominant mutations with dosage 
effect.  
4.3 Application to clinical practice 
Gene identification studies gain their most important roles in clinical medicine. 
The major role of disease gene identification studies is to obtain an understanding of the 
genetic bases of diseases. The application of whole exome sequencing to clinical 
diagnosis is already being used with high success rates (139, 140). Clinical diagnosis 
through sequencing technologies allows the recognition of the risk of recurrence in 
subsequent pregnancies, and provides guidance and prognosis. For example, the NIH 
Undiagnosed Diseases Program aimed to provide answers to patients with an 
undiagnosed condition using high density SNP arrays, or whole exome and whole 
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genome sequencing (139). In the first year, 326 patients were accepted where 53% of 
them had an unknown neurological disorder. 24% of all participants were diagnosed on 
clinical, biochemical, pathologic or molecular grounds (139). This saves patients from 
the pain, cost and time of additional test, and provide them a definite diagnosis (141).  
In addition to clinical diagnosis, the information obtained from the genomic data 
will be used as a source of personalized medicine which aims “to provide the right 
treatment to the right person at the right time” (142). As the technology improves, 
sequencing becomes affordable to gain an understanding of the pathophysiological 
mechanisms and biochemical pathways underlying disorders (35). Understanding of the 
biology of disease process can be obtained by identifying multiple associated genes that 
affect one biological pathway. Detection of mutations in proteins that are known to be 
involved in protein degradation, mitochondrial and endoplasmic reticulum homeostasis, 
and axonal transport strongly supports that defects in these mechanisms can result in 
neurodegeneration. Moreover, chronic exposure to certain toxic chemicals can trigger 
the defects in these pathways and can also result in neurodegeneration. The main aim 
would be to develop suitable therapeutic targets for these common pathways. All of 
these mechanisms leading to neurodegeneration can act synergistically for a single 
neurodegenerative disorder. Most proteins serve many diverse functions adding them 
into more than one pathway. When considering the treatments for neurodegenerative 
disorders, it is important to know which one of these pathways to target at which 
particular stage of the disease (141). As a future perspective, scientists should focus on 
the identification of new genes in shared pathways; and their analysis in animal models 
will deepen our knowledge in the pathophysiological consequences of neurological 
dysfunctions.  
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Appendix A 
Accession codes 
 
Accession codes for HTRA2 orthologs  
Ailuropoda melanoleuca:  XP_002921511 
Callithrix jacchus:   XP_002757664 
Equus caballus:   XP_001500096 
Gallus gallus:    XP_423666 
Homo sapiens:   NP_037379 
Monodelphis domestica:  XP_001376681 
Mus musculus:    AAH49880 
Oryctolagus cuniculus:  XP_002709758 
Pan troglodytes:   NP_001267074 
Rattus norvegicus:    NP_001100069 
Sus scrofa:    XP_005674479 
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Accession codes for SPG20 orthologs  
Ailuropoda melanoleuca:  XP_002928833 
Callithrix jacchus:   XP_008996381 
Caenorhabditis elegans:  F57B10.9 
Danio rerio:     NP_001107130.1 
Equus caballus:   XP_005601198 
Gallus gallus:    XP_417098.1 
Homo sapiens:   NP_055902 
Monodelphis domestica:  XP_007495391 
Mus musculus:   NP_659144 
Oryctolagus cuniculus:  XP_002720632 
Pan troglodytes:   XP_003314171 
Rattus norvegicus:   XP_006232427 
Sus scrofa:    XP_005668402 
Tetraodon nigroviridis:  CAG09018 
Xenopus (Silurana) tropicalis: NP_001123727.1 
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Appendix B 
Regions identical by descent in 5 affected relatives of ET-1 
family 
 
 
Figure B. Heterozygous or homozygous identical by descent regions with at least 3 MB 
in length, and shared by 5 affected relatives of ET-1 family. Red lines: IBD regions; red 
circles: homozygous regions  
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Table B. Heterozygous or homozygous identical by descent regions with at least 3 MB 
in length, and shared by 5 affected relatives of ET-1 family. HTRA2 p. G399S is on 
chromosome 2p (bold), in the longest region IBD shared by the 5 affected individuals 
based on our SNP analysis.  
Chr  Start End Size (Mb) 
2  45,999,820 75,128,176 29.1  
3  50,113,035 53,332,706 3.2  
5  109,518,552 135,395,203 25.9  
7  71,597,460 74,715,724 3.7  
8  90,352,835 94,092,917 3.7  
13  31,642,859 37,144,848 5.5 
13  38,350,194 43,421,683 5.1  
15  40,549,618 45,142,419 4.6  
15  53,016,092 58,635,583 5.6  
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Appendix C 
Primer List 
 
Table C1. Primers used for PCR amplification and haplotype analysis of ET-1 family. 
Primer Name Direction Sequence 
Segregation 
 
 
EML6 
F CTGAGCTTGGGTTTGGAGAA 
R CAGATCCTGCACAGACTTGG 
HTRA2 
F ATGCCTGGGTTTGGCTAATA 
R CAACTGGGATTGGGTTCG 
NUP210 
F GTGTGAAGAGACGGCAGTGA 
R TGTGAGAGTGTCCTGGGTGA 
UVSSA 
F AATGAAGATGGGAAGGCAGT 
R AGTGGTAGCCCAAGGCAAG 
TBC1D7 
F AAACTAACCCTCAGGCCAAC 
R GGGTTTGGGATAAAGTTGTGAG 
ALDOB 
F GCTTCCTTCTTTACTTGCCTTC  
R GGGTCCCTCGCACTAATACA 
SETX 
F GGCTCAGGACACTGACGAA 
R CCAATGGCTGAAGATCCTGT 
ANKRD33 
F CCCACATCAGTCTTGCTCCT  
R GTGGCAGTCACAAGGTGGTC 
LTK 
F TACAGGAGGGAGGAGGTGAA  
R TCATCCACAGGTTAGGAGCA 
GCOM1 
F GGCCATTTCCTTATGTTCCA  
R GCTGTTTCTGAAGTGCCAAG 
ANPEP 
F GGCTGGAGACTTTGTCCTTG  
R AGCTCCTCCTCAAGGCTGTT 
MYO1D 
F TGGAGCAATCTCAAAGAGGA  
R CTAAGCAAGCAACCACCACA 
PLA2G4C 
F CAGAAGTTCGTTGGATGTGG  
R CCTGGTGGATGCTGGTTTAG 
Coding regions 
  
HTRA2_1 
F GTCCTACTGTCCGCCTGCT 
R CTGTGACCACGGCCTCATAC 
HTRA2_2 
F TGTGGTGGAGAAGACAGCAC 
R AGAGCTAACAATGCCGGATG 
HTRA2_3 
F CGCTGAGGATTCAGACTAAGG 
R CTTGGAAGGAAGGATGTCTCA 
HTRA2_4 
F TCAGTGTGGGAAGGGTAGGT 
R GACAGAAATGAGAACAAAGCTCA 
HTRA2_5 F TTGATGAGAGACTTGAGGTGGA 
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R AGGAGTCAGTGCTGGTGGTT 
Regulatory 
regions 
  
HTRA2_3UTR 
F TGAGGCTCCTGCTCTGATTT 
R AGCATGGGAATCTTTGCTC 
HTRA2_5UTR1 
F CCTCGTGGAAGCACAGAATC 
R GGACACAGGAGGTGGTGACT 
HTRA2_5UTR2 
F TCACGGTGCTACAGGTGGTA 
R GAGCGGCTCTTTGACTCG 
HTRA2_5UTR3 
F CGAGCAGTAGGAAGCAGTCA 
R AGCAGGCGGACAGTAGGAC 
STRs 
  
HTRA2_74.259 
F FAM-GGGAGGAGTTGTGAGAATGC 
R GTTTCTTAGCACACAAGAACCAGGTCA 
HTRA2_74.324 
F HEX-AGCAGGTCACAGAATAGCATGT 
R GTTTCTTTTTAGATGACTACCCAGACATTTG 
D2S2977 
F FAM-GGCAGCACAGTGACAGATAA 
R GTTTCTTCTTCCCCAATCAACTCTCCT 
D2S1394 
F FAM-GGCATCTTTATCCTTAGCCC 
R GTTTCTTCGGGGTCTGCATTACAGTAT 
SNPs 
 
 
rs11674899 
F TTCAAGTGACATTCAAGAGAGAGC 
R GTGAGGGTGGAGAGACCAGA 
rs3771770 
F AGTGGCCTGACTCTTGTCGT 
R GACTACCTCCTCAGTGCTTTCA 
 
Table C2. Primers used for PCR amplification ET-4 family. 
Primer Name Direction Sequence 
SPG20 
F TGTCCTGTTTGTGTTGCAGTT 
R GCCAAAGTCTGGTTAAGGTAGAA 
CSNK1A1L 
F CAGCCCACGACAGTAGTTCA  
R ATGGGTACTGGGCGTCACT 
C17orf70 
F CCTTAGTGAGCGACCCACAG  
R CAGAGCAGGTTCTTGCCATT 
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Appendix D 
Allelic discrimination plot 
 
Figure D. Allelic discrimination plot of TaqMan genotype data of HTRA2 p.G399S 
variant in 183 individuals. The squares show NTC samples. Allele A homozygote 
clusters at the upper left corner, allele G homozygotes cluster at the lower right corner. 
Two heterozygotes cluster in the middle.  
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Appendix E 
Percentage of targeted bases covered at particular depths. 
 
 
Figure E1. Percentage of targeted bases covered with whole exome sequencing of ET-1 
family at particular depths.  
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Figure E2. Percentage of targeted bases covered with whole exome sequencing of ET-4 
family at particular depths.  
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Appendix F 
Linkage to Previously reported ETM loci 
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Figure F. Essential tremor in family ET-1 is not linked to DNAJC13 or to genomic 
regions previously reported to be associated with essential tremor. At each region, the 
haplotype shared by the affected father-daughter pair IV:4 and V:8 is indicated in pink. 
At none of these regions was this haplotype also shared by the other affected family 
members. 
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